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S01-01
Canadian neurochemists and roles in ISN/ASN
P. Beart
University of Melbourne, Florey Institute of Neuroscience & Mental
Health, Parkville, Australia
Canadians have made diverse contributions to neurochemistry,
including notable scientiﬁc advances, service to ISN and Journal of
Neurochemistry (JNC). The 17 Canadian members at ISN’s
foundation (1967) came from different areas of biochemistry,
physiology and medicine. First ISN Chairman (1967-69) Roger
Rossiter, Professor of Biochemistry, University of Western Ontario,
was truly international being an Oxford trained Australian. Other
ISN Presidents were Allan Boulton (1984-7) and Roger Butterworth
(2007-9). Canadian representation on ISN Council has been limited,
but consistent through the years, with Theodore Sourkes and
Leonhard Wolfe important contributors in 1970s. Historically,
prominent Canadian neurochemists contributed to 1st Meeting of
Section of Neurochemistry of American Academy of Neurology
(Boston, 1957), Juda Quastel was a member of Commission of
Neurochemistry (1959) and Theodore Sourkes was a member of ﬁrst
elected ASN Council (1971). Allan Boulton was only non-USA
President (1995-7) of ASN, which has held a single meeting in
Canada (Vancouver, 1976). Vancouver was also site of the ﬁrst ISN
Meeting in Canada (1983) with Patrick and Edith McGeer both
members of Local Organizing Committee. Marco Prado is Chair-
person of Local Host Committee for 2019 Montreal ISN-ASN
Meeting. Before ISN owned JNC (1970) Roger Rossiter, Alan
Elliott and Juda Quastel, who were active in international neuro-
chemical symposia in 1950s, served on its Editorial Board. Elliott
and Quastel were co-authors on the landmark neurochemical text
book with Irvine Page, “The Chemical Dynamics of Brain and
Nerve” (1955). Some 15 Canadians have served on Editorial Board
of JNC with Allan Boulton (1990-5) and Brian Collier (1996-2006)
being Chief Editors. There have been notable Canadian contribu-
tions to growth of neurochemical knowledge across the basic
neurochemistry of synaptic transmission (GABA, acetylcholine,
catecholamines), lipid biochemistry, and understanding neu-
ropathologies.
S01-02
Foundation of ASN and ISN and key USA names
A. Boullerne
University of Illinois at Chicago, Department of Anesthesiology,
Chicago, USA
Neurochemistry emerged in USA after World War II, fueled by
generous funding and new technologies– electron microscope,
nuclear magnetic resonance, lipid extraction. . . Another driving
force was neurochemical societies traced back to Francis Otto
Schmitt 1949-1950 bimonthly neuroscience seminars at the
Massachusetts Institute of Technology. The ﬁrst international
neurochemical forum was held in 1954 in Oxford, followed by
national and international neurochemical conferences across the
Atlantic and in Japan. Early organizer Russian-born Eugene
Roberts at Washington University had discovered in 1950
gamma-Aminobutyric acid (GABA) in brain. In 1967, the Inter-
national Society for Neurochemistry (ISN) was founded by four
key players: Americans Jordi Folch-Pi and Heinrich Waelsch, and
British Henry McIIwain and Derek Richter. ISN founder Alfred
Pope at Harvard McLean Hospital did small sample analysis in
1952 that lead to anticholinesterase treatment in dementia. Amer-
ican Society for Neurochemistry (ASN) founded in 1969 by Folch-
Pi, Donald Tower and Wallace Tourtellotte held its ﬁrst annual
meeting in spring 1970. Bernard Agranoff, pioneer of inositol
signal transduction, had ASN sponsor the ﬁrst Basic Neurochem-
istry textbook in 1972. Spanish-born Folch-Pi outstanding McLean
Hospital research head founded complex lipid structural chemistry,
and his charismatic personality contributed to formal recognition of
ISN and ASN. Folch-Pi student Marjorie Lees puriﬁed in 1951
myelin protein Proteolipid and together reported in 1957 a now
classic method for brain lipid extraction. In 1970 Julius Axelrod
won Nobel prize for neurotransmitter re-uptake, and in 1971 Earl
Sutherland won Nobel prize for cyclic AMP second messenger. In
1973, William Norton at Einstein College devised a sucrose
gradient launching puriﬁed myelin molecular era, while Richard
Quarles (NIH) discovered the ﬁrst glycoprotein Myelin-Associated
Glycoprotein. USA has proved a formidable force driving neuro-
chemistry and hopefully will continue.
S01-03
Fine brains of Latin America: ﬁve decades of ﬂourishing
neurochemistry in the region
J. Pasquini
Universidad de Buenos Aires, Departmento de Quimica Biologica,
Buenos Aires, Argentina
Latin American neurochemistry was born in different countries
between the 1950s and 1960s with different degrees of represen-
tation and participation. Right from the start, neurochemistry was
very prominent in Venezuela, Argentina, Mexico, Uruguay, Chile
and Brazil. As a matter of fact, due to the important development of
neuroscience en Venezuela, ISN organized the ﬁrst meeting in Latin
America in La Guaira, Venezuela, in 1987, the second one in
Buenos Aires, Argentina, in 2001, and the third one in Cancun,
Mexico. In terms of leading researchers in the ﬁeld, Venezuela gave
us the outstanding work of Boris Drujan, Horacio Vanegas and
Miguel Laufer. Argentina was the home of Eduardo De Robertis,
Ranwell Caputto and Eduardo Soto. In turn, Uruguayan neuro-
chemistry had a key ﬁgure in Clemente Estable, while Chilean
neurochemistry gave us the ﬁne work of JoaquınLuco Valenzuela.
Finally, Mexico had prominent neuroscientists in Ricardo Tapia and
Herminia Pasante. Brazil instead was more prone to biophysics and
neurophysiology with important names like Miguel Covian and
Carlos Chagas Filho, under whose direction at the Institute of
Biophysics Rita Levi Montalcini conducted crucial experiments for
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the discovery of the neural growth factor after the Second World
War. After this brief introduction, we will take a look at the
development of neurochemistry in Latin America, all those scientists
who make everyday efforts for the growth of neuroscience in each
country, and how the neuroscience map has changed over the years.
S01-04
Julius axelrod: the second act was a smash
J. Coyle1
1Mclean Hospital, Mailman Research Center, Belmont, USA
2Harvard University, Psychiatry, Cambridge, USA
Julius (“Julie”) Axelrod was born in 1912 in the lower
Manhattan, the son of Polish-Jewish immigrant parents. His father
supported the family as a basket weaver. In 1933, Julie graduated
from tuition-free City College of New York with a BS in Biology.
Rejected from several medical schools, he took a position as a
technician testing vitamin supplements at the Laboratory of
Industrial Hygiene, where he remained for 11 years. During that
time, he married, had 2 sons and completed a Masters in Chemistry.
In 1946, Bernard Brodie hired him as a technician at the Goldwater
Hospital. Julie joined Brodie at National Heart Institute in 1949
where he published nearly 30 papers on drug metabolism. Disen-
chanted with the lack of recognition, he enrolled in the PhD program
in Pharmacology at George Washington University, completing it in
a year. The National Institute of Mental Health appointed him the
Chief of the Section on Pharmacology in 1957 at the age of 45. Over
the next dozen years, he published over 20 reports in Science and
Nature on the disposition of biogenic amines including deﬁning the
mechanism of action of antidepressant drugs. He received the Nobel
Prize in Medicine in 1970. He hired his ﬁrst post-doctoral fellow in
1962: Lincoln Potter, MD. Over the next 20 years, a score of
distinguished scientists trained in his laboratory including Richard
Wurtman, MD, Solomon Snyder, MD, Leslie Iversen, PhD, Jacques
Glowinski, MD, Jacques de Champlain, MD, Ira Black, MD, Perry
Molinoff, MD, Richard Weinshilboum, MD, Juan Saavedra, MD,
Fred Wooten, MD, Michael Brownstein, MD, Roland Ciaranello,
MD, Ronald Holz, MD, PhD, Joseph Coyle, MD, Steven Paul, MD,
PhD, Manny Diberto, MD, Warren Strittmater, MD, and Fulton
Crews, PhD.
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S02 Dysfunction at the presynapse
S02-01
Neurodevelopmental synaptopathies: presynaptic
dysfunction in intellectual disability
S. Gordon
Florey Institute of Neuroscience and Mental Health, University of
Melbourne, Parkville, Australia
Neurodevelopmental disorders (including intellectual disability,
autism spectrum disorder and movement disorders) affect 2-5% of
children worldwide. The cause of neurological impairment in the
vast majority of individuals with these brain disorders remains
unknown, however advances in gene technology is now enabling
the identiﬁcation of novel substrates underlying neuronal dysfunc-
tion. This provides a new starting point for understanding the
relationships between speciﬁc genetic mutations, brain function,
neurodevelopment and cognition. Moreover, this provides a novel
avenue for uncovering the molecular mechanisms underlying
normal protein function. Importantly, mutations in proteins involved
in neurotransmitter release and synaptic vesicle cycling have been
identiﬁed in a range of neurodevelopmental disorders, including
intellectual disability, epilepsy, and autism spectrum disorders.
Alterations to the efﬁciency with which exocytosis or endocytosis
occurs have adverse effects on neurotransmitter release, and
therefore all coordinated neuronal activity. Newly identiﬁed muta-
tions in key presynaptic proteins including synaptotagmin-1 and
synaptophysin have been found in children with intellectual
disability. We used model systems to examine the effect on these
mutant proteins on presynaptic function, revealing mutation-speciﬁc
effects on exocytosis, endocytosis and protein trafﬁcking. These
ﬁndings provide a framework for unravelling how disruption to
synaptic vesicle dynamics and neurotransmitter release produces
overlapping and distinct clinical phenotypes.
S02-02
Altered synaptic vesicle recycling in huntington’s disease
K. Smillie1, R. McAdam1, S. Gordon2, M. Cousin1
1University of Edinburgh, Centre for Discovery Brain Sciences,
Edinburgh, United Kingdom
2University of Melbourne, Florey Institute, Melbourne, Australia
Neurodegenerative diseases affect millions of people worldwide
and with society generally living longer, this means the number of
affected individuals is increasing. This creates a need to understand
the molecular mechanisms in order to develop new treatments. An
emerging theme in neurodegenerative diseases, including Hunting-
ton’s Disease (HD), is the premise that early presynaptic dysfunction
plays a role towards later pathological outcomes. Huntington’s
disease is an inherited autosomal dominant disease whereby affected
individuals have extended numbers of a CAG repeat in the
huntington gene. When translated, this results in an expanded
polyglutamine stretch in the huntingtin protein (htt) likely causing
altered protein function. One of the early hallmarks of neurodegen-
eration in HD is synaptic atrophy in the striatum potentially caused
by failure of efﬁcient neurotransmission. Synaptic failure can be
caused by an inability of the presynaptic nerve terminal to maintain
neurotransmitter release, through either defects in exocytosis or in
the subsequent endocytic processes required to retrieve the excess
membrane and recycle synaptic vesicle proteins. We have uncov-
ered activity-dependent signatures of presynaptic dysfunction in
primary neuronal cultures from a knock-in mouse model of HD
(httQ140/Q140). Furthermore, we have shown that this is due to loss of
wt htt function and can be rescued with expression of wt htt in the
httQ140/Q140 background. These results suggest that presynaptic
dysfunction in HD may render neurons susceptible to repeated
insults, culminating in synapse failure and degeneration. Under-
standing the molecular basis could lead to identiﬁcation of new
pathways for future therapeutic intervention.
S02-03
Molecular mechanisms underlying STXBP1/MUNC18-1
linked encephalopathies and rational rescue strategies
J. Burre1, N. G. L. Guiberson1, A. Pineda1, D. Abramov1, P. Kharel1,
K. E. Carnazza1, Rachel. T. Wragg2, J. S. Dittman2
1Weill Cornell Medicine, Brain and Mind Research Institute, New
York, USA
2Weill Cornell Medicine, Biochemistry, New York, USA
Heterozygous de novo mutations in the neuronal protein
STXBP1/Munc18-1 are linked to epilepsies, intellectual disability,
movement disorders, and neurodegeneration. These devastating
diseases have a poor prognosis and no known cure, due to lack of
understanding of the underlying disease mechanism. To determine
how mutations in Munc18-1 cause disease, we use newly generated
S. cerevisiae strains, C. elegans models, and conditional Munc18-1
knockout mouse neurons expressing wild-type or mutant Munc18-1,
as well as in vitro studies. We ﬁnd that at least ﬁve disease-linked
missense mutations of Munc18-1 result in destabilization and
aggregation of the mutant protein. Aggregates of mutant Munc18-1
incorporate wild-type Munc18-1, depleting functional Munc18-1
levels beyond hemizygous levels. We demonstrate that the three
chemical chaperones 4-phenylbutyrate, sorbitol, and trehalose
reverse the deﬁcits caused by mutations in Munc18-1 in vitro and
in vivo in multiple models, offering a novel strategy for the
treatment of varied encephalopathies.
S02-04
Function and dysfunction of the PD related LRRK2 protein
at the presynaptic site
G. Piccoli
Universita degli Studi di Trento, Department of Cellular,
Computational and Integrative Biology - CIBIO, Trento, Italy
Parkinson’s disease (PD) is characterized by the progressive
degeneration of dopaminergic neurons within the substantia nigra
pars compacta and the formation of protein aggregates in surviving
neurons. LRRK2 G2019S mutation is the major determinant of
© 2019 The Authors
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familial PD cases and leads to late-onset PD with pleomorphic
pathology, including alpha-synuclein accumulation and deposition
of protein inclusions. LRRK2 G2019S mouse model demonstrates
an age-dependent motor and cognitive impairment. We observed the
presence of aggregates containing N-ethylmaleimide sensitive factor
(NSF) in basal ganglia specimen from G2019S carrier PD patients
and in cellular and animal model expressing LRRK2 G2019S
variant. We found that LRRK2 G2019S kinase activity affects NSF
degradation and induces its accumulation in toxic aggregates.
Noteworthy, induction of autophagy cleared NSF aggregation and
rescued motor and cognitive impairment observed in aged hG2019S
BAC mice. We suggest that LRRK2 G2019S pathological phos-
phorylation hampers substrates catabolism thus causing the forma-
tion of cytotoxic protein inclusions.
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S02 Dysfunction at the presynapse
S03 Complement: sculpting the developing and diseased brain
S03-01
Complement and blood-brain barrier integrity
J. Alexander
University at Buffalo, Medicine, CTRC 8030D, USA
Emerging evidence highlights the critical role of the dysfunc-
tional blood-brain barrier (BBB) in initiation and perpetuation of
brain pathology in neuroinﬂammatory settings. Activation of the
network of complement proteins in these settings results in the
release of byproducts such as anaphylatoxins C3a and C5a, which
forms a part of the clinical proﬁle in diseases such as lupus. In the
studies described here, in vitro 2D BBB model that closely emulates
the BBB in vivo, constructed using human brain microvascular
endothelial cells (HBMVEC) and astroglial cells, helped understand
the role of complement in alteration of BBB integrity. Our data
demonstrate that in lupus and other inﬂammatory settings, the
proteins generated on complement activation along with other
factors such as oxidative stress and calcium channel function
compromise the endothelial cells. The endothelial layer has
increased permeability monitored by changes in transendothelial
electrical resistance. The cells are reprogrammed into a proinﬂam-
matory phenotype with altered tight junctions such as claudin-5 and
zona occludens, cytoskeletal remodeling, as well as matrix function
and viability resulting in a ‘leaky’ BBB. In addition, NFkB signaling
is altered with transition from the cytoplasm into the nucleus.
Bioenergetics via mitochondrial function is impaired by comple-
ment activation along with bioenergy-sensing signals by AMPK and
SIRT1. Gaining insight into the complexity of complement
mediated signaling in inﬂammatory and reparatory processes in
endothelial cells will help identify effective therapeutic targets to
combat inﬂammation in different settings and will bring the ﬁeld
one-step closer to understanding the translational potential of these
targets.
S03-02
Complement C3A shapes the plasticity of the post-stroke
brain
M. Pekna
University of Gothenburg, Institute of Neuroscience and Physiology,
Gothenburg, Sweden
Complement is part of the innate immune system that plays a
major role in the initiation of inﬂammation and host defence against
pathogenic bacteria. C3a is a 77 amino acid, 9 kDa peptide
generated through the proteolytic activation of the central molecule
of the complement system, the third complement component, C3.
C3a exerts its functions through a G-protein coupled receptor,
C3aR, that is expressed by many cell types including neurons and
glia. This talk will discuss recent insights into the novel roles of
C3a-C3aR signaling in the CNS with focus on synaptogenesis,
axonal plasticity and regulation of reactive gliosis. I will also present
ﬁndings from our laboratory pointing to C3aR as a target for
therapies aiming at improving recovery after ischemic stroke and
birth asphyxia.
S03-03
Deciphering key roles for complement peptide receptors
in brain development
T. Woodruff, O. Hawksworth, J. Lee, L. Coulthard
The University of Queensland, Faculty of Medicine, Brisbane,
Australia
Complement is an important immune system that has key
pathogenic roles in the adult brain during neurodegeneration.
However, emerging roles for complement in neurodevelopmental
diseases have also been documented. Whilst signiﬁcant attention has
been focused on classical complement components, C1q and C4,
and their roles in synaptic pruning, less is known about the roles of
the ‘anaphylatoxins’ C3a and C5a, which are generated by all
pathways of complement activation. Here we present data demon-
strating essential physiological roles of C3a and C5a receptors
during the neurogenic period of mammalian neurodevelopment. We
utilized in vivo and in vitromodels to modulate anaphylatoxin
receptor (C3aR, C5aR1) function during critical periods of neuro-
genesis. Human development was modelled using human embry-
onic stem cells differentiated to form neural rosettes, or cultured as
neurospheres. We show marked conservation in localization of
C5aR1 and C3aR expressed on neural progenitor cells in both
human and mice. Both receptors are expressed on the apical
membrane of neural progenitors, and C5aR1 promotes their
proliferation through activation of PKCz, a known mediator of
polarity. In vivo, transient inhibition of C5aR1 through in uteroin-
jection of complement inhibitors to the embryonic ventricle resulted
in a reduction of proliferating cells at the ventricular surface. In
contrast, C3aR inhibition increased proliferation at this site, and
in vitro experiments mimicked these ﬁndings. Remarkably, mice
subjected to brief and transient pharmacological C5aR1 blockade
during development demonstrated behavioral abnormalities and
MRI-detected microstructural alterations in adulthood. Our current
research is focused on identifying the source(s) of complement C3a
and C5a in the embryo, and roles for other terminal complement
proteins in embryonic neurogenesis. Together, these data demon-
strate fundamental roles for complement anaphylatoxin receptors in
the normal development of the embryonic mammalian brain.
S03-04
Complement: the culprit in neurodegeneration?
C. Lemere1,2
1Brigham and Women’s Hospital, Ann Romney Center for
Neurologic Diseases, Boston, USA
2Harvard Medical School, Neurology, Boston, USA
Background: Complement is the body’s host defense system
against pathogens and is involved in microglia-mediated synaptic
pruning during brain development. Complement is elevated in
Alzheimer’s disease (AD) brain and appears to contribute to the
response to amyloid-b (Ab) oligomers in early pre-plaque stages.
Therefore, we asked whether complement plays a role in brain aging
and/or later stages of AD pathogenesis.
© 2019 The Authors
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Methods: We crossed an amyloid model of AD, APPswe/
PS1dE9 Tg mice, with complement C3 germline knockout (C3 KO)
mice. Male APP/PS1;C3 KO mice, wildtype (WT), APP/PS1 and
C3 KO mice were compared for cognitive ﬂexibility using the Water
T Maze (WTM) at 16 months of age. Ab plaque load, gliosis,
hippocampal synaptic changes and neuron number were evaluated.
We also generated an inducible C3 KO mouse model (C3 ﬂ/ﬂ;UBC-
Cre-ERT2) (C3iKO) in which tamoxifen treatment leads to global
knockdown of C3.
Results: Lifelong C3-deﬁciency improved cognitive ﬂexibility in
APP/PS1 mice even though they had more Ab plaque deposition at
16 months of age. Although the number of hippocampal glia did not
change, fewer microglia were recruited to the plaques and plaque-
associated microglia appeared to be less activated in the C3-deﬁcient
APP/PS1 mice. Hippocampal synapses and neuron numbers were
rescued by C3-deﬁciency in APP/PS1 mice. Tamoxifen treatment of
9 mo-old male C3iKO mice to globally knockdown C3 expression
led to reduced C3 protein levels in plasma, an increase in synaptic
puncta, and improved LTP in hippocampal slices 3 months later.
Current studies are underway to determine whether C3 lowering is
protective in early stage neurodegenerative diseases.
Conclusions: Complement signaling appears to play a key role
neuronal health and function in the aging brain and AD.
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S04 Glutamate at the crossroad
S04-01
The energetic cost of not resting
C. Rae
The University of New South Wales, Neuroscience Research
Australia, Sydney, Australia
While it is generally well accepted that increased glutamatergic
activity results in increased metabolic activity, the metabolic impact
of inhibitory (GABAergic) activity is less well understood.
Inhibitory activity requires membrane hyperpolarization which is
energetically expensive but it can also induce a global downturn in
metabolic activity. This means that the balance between hyperpo-
larization and metabolic inhibition can determine whether or not
there is a global increase or decrease in brain energy consumption
[1].
The mechanism of excitatory stimulation is important, with some
routes tolerated better than others [2,3]. The interplay of different
cell types and compartments is highly important when interpreting
what a metabolic proﬁle represents: Normal metabolic activity?
Overstimulation? Hyperexcitability? Metabolic exhaustion [4]?
Similarly, the mechanism of inhibitory input is also crucial.
Delivered in just the right place, tiny amounts of GABA can have
immensely strong inhibitory effects through activity at “master”
switch GABAergic receptors [5].
How the system reacts depends on the baseline metabolic
situation. Systems which are perturbed from the typical “resting”
situation may react differently to input. This is an important
consideration when designing interventions in clinical populations
as baseline status may predict response [6].
1. Nasrallah F. et al. (2007) Journal of Cerebral Blood Flow and
Metabolism 27, 1510-1520
2. Rae C. et al. (2006) Journal of Cerebral Blood Flow and
Metabolism 26, 1005-1017.
3. Rae, C. et al (2005) Journal of Neurochemistry 92, 405-416
4. Miller et al (2017) Sleep 40, zsx148
5. Nasrallah et al, (2011) Journal of Neuroscience Research 89,
1935-1945
6. Rae et al (2013) International Journal of Neuropsychophar-
macology 16, 1695-1706
S04-02
Glutamate-glutamine cycling and oxidative metabolism in
astrocytes from the perspective of magnetic resonance
spectroscopy in vivo
J. Duarte1
1Lund University, Department of Experimental Medical Science,
Lund, Sweden
2Lund University, Wallenberg Centre for Molecular Medicine,
Lund, Sweden
Astrocytes play an important role in glutamatergic neurotrans-
mission, namely by clearing synaptic glutamate and converting it
into glutamine that is transferred back to neurons. The rate of this
glutamate-glutamine cycle is known to couple to that of glucose
utilization and of neuronal metabolism. On the other hand,
astrocytes are often considered to be glycolytic cells with meagre
mitochondrial oxidative metabolism. Magnetic resonance spec-
troscopy has been used for 13C tracing experiments in vivo, namely
for detecting labelling incorporation from [13C]glucose into brain
amino acids. Such approach allows to determine rates of energy
metabolism in neurons and astrocytes, and the glutamate-glutamine
cycle. Recent work in the cerebral cortex of animal models suggests
that variations of the glutamate-glutamine cycle rate upon cortical
stimulation are coupled to the rates of mitochondrial metabolism in
both neurons and astrocytes. Moreover, while the rate of resting
energy metabolism is slower in astrocytes than neurons of the cortex
in vivo, somatosensory stimulation induces oxidative metabolism
increments of similar magnitude in the two cell types. This is in line
with an active role of astrocyte bioenergetics in glutamatergic
neurotransmission, which may be key in disorders characterised by
dysfunction of excitatory synapses.
S04-03
Glutamate homeostasis revisited - neuronal transport and
metabolism
H. Waagepetersen, L. McNair, Sofie. K. Christensen, Jens. V.
Andersen, Blanca. I. Aldana
University of Copenhagen, Drug Design and Pharmacology,
Copenhagen, Denmark
Glutamate homeostasis ismainly thought to be regulatedwithin the
frame of the glutamate -glutamine cycle. Vesicular glutamate release
from the pre-synapse, uptake via high-afﬁnity glutamate transporters
in astrocytes, conversion of glutamate to glutamine and ultimately
transfer of glutamine to the neuron and deamidation to glutamate. In
addition, the importance of glutamate oxidation via glutamate
dehydrogenase (GDH) has primarily been addressed mainly in
astrocytes. However, it is now clear that presynaptic glutamate uptake
via neuronal GLT1 (nGLT1) (McNair et al. 2019) is of functional
importance and knock out of nGLT1 leads to disturbed amino acid and
energy homeostasis and reduced oxidation of glutamate. In addition,
glutamate oxidation via GDH (Hohnholt et al 2017) is essential in
neurons for maintenance of the energetic machinery especially during
increased energetic demand. We have preliminary data showing that
enzymes, associated with glutamate metabolism is signiﬁcantly
affected in neurons derived from iPSCs of patients suffering from
dementia. Interestingly, also the human isoform of GDH, i.e. GDH2,
is affected, underlining the importance of employing a human model
to study neurodegenerative pathologies. Overall, we hypothesize that
GDH is important to sustain capabilities of neuronal mitochondria by
maintaining a minimum amount of TCA cycle intermediates neces-
sary during energetic demands induced by neuronal activation.
References:
Glutamate dehydrogenase is essential to sustain neuronal oxida-
tive energy metabolism during stimulation. Hohnholt et al. J Cereb
Blood Flow Metab. 2017. Deletion of Neuronal GLT-1 in Mice
Reveals Its Role in Synaptic Glutamate Homeostasis and Mito-
chondrial Function. McNair et al. J Neurosci. 2019
© 2019 The Authors
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S04-04
Point-Counterpoint: glutamate production and oxidation
D. Rothman
Yale University, Biomedical Engineering & Radiology and
Biomedical Imaging, New Haven, USA
The abstract has not been provided.
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S04 Glutamate at the crossroad
S05 Reactive astrocytes in waste clearance and regeneration - context-
dependent responses and treatment opportunities
S05-01
Reactive gliosis as a target - why and when
M. Pekny
University of Gothenburg, Department of Clinical Neuroscience,
Gothenburg, Sweden
The abstract has not been provided.
S05-02
Reactive gliosis and the consequences for cognition in
stroke and alzheimer’s disease
E. Hol
UMC Utrecht Brain Center, Translational Neuroscience, Utrecht,
Netherlands
Astrocytes are essential for the maintenance of CNS homeostasis
and normal CNS function. In chronic neurodegenerative disorders
(e.g. Alzheimer’s disease1) and in acute neurological disorders (e.g.
stroke2) astrocytes become activated and change both morphology
and function. In response to astrocyte-derived signals, microglia
remove synapses in a complement system-dependent manner. Two
cellular hallmarks of reactive astrocytes are hypertrophy of their
processes and upregulation of the part of the cytoskeleton known as
intermediate ﬁlaments, which are composed of glial ﬁbrillary acidic
protein (GFAP), vimentin, nestin, and synemin. These intermediate
ﬁlaments are highly dynamic structures that are involved in cell
signalling, both in health and disease3–5. We have shown in a mouse
model for Alzheimer’s disease that reactive astrocytes have an
altered expression of genes coding for extracellular matrix proteins,
neuron-supporting genes, and immune response-related genes6,7.
This implies a change in astrocyte-microglia and astrocyte-neuron
interaction. We are now beginning to understand what the functional
consequences are of reactive gliosis, how reactive gliosis can
contribute to cognitive decline, and what the function is of
intermediate ﬁlaments in these processes.
1 Osborn LM et al. Prog Neurobiol 2016; 144: 121–141.
2 van Dijk BJ et al. Biochim Biophys Acta - Mol Basis Dis 2016;
1862: 492–505.
3 Middeldorp J, Hol EM. Prog Neurobiol 2011; 93: 421–443.
4 Pekny M et al. Acta Neuropathol 2016; 131: 323–45.
5 Hol EM, Pekny M. Curr Opin Cell Biol 2015; 32: 121–130.
6 Kamphuis W et al. Glia 2015; 63: 1036–1056.
7 Orre M et al. NeurobiolAging 2014; 35: 2746–2760.
S05-03
Astrocytes and waste clearance in CNS – from physiology
to intervention opportunities
M. Nedergaard
University of Rochester Medical Center, Nedergaard Lab,
Rochester, USA
The abstract has not been provided.
S05-04
Astroglia deﬁne plasticity responses in the diseased brain
A. Verkhratsky
The University of Manchester, Faculty of Biology, Medicine and
Health, Manchester, United Kingdom
The common and prevailing set of neurological thoughts
considers neurones as the primary substrate of pathological
progression. This “ neurone-centric” concept, however, undergoes
a rapid change. It has become universally acknowledged that the
homeostasis of the nervous tissue is regulated by a complex fabric of
neuroglial cells. Astroglia in particular represent a main element in
the maintenance of homeostasis and providing defence to the brain.
Consequently, dysfunction of astrocytes underlies many, if not all,
neurological, neuropsychiatric and neurodegenerative disorders.
Astrogliopathology comprises diametrically opposing morpho-
functional changes in astrocytes, i.e. their hypertrophy along with
reactivity or atrophy and astrodegeneration with asthenia. These
complex plastic changes underlie pathophysiology of all neurolog-
ical disorders including genetic (e.g. Alexander disease, which is a
primary astrogliopathy), environmentally caused (e.g. heavy metal
encephalopathies or hepatic encephalopathies), neurodevelopmental
(e.g. different forms of autistic spectrum disorder), neuropsychiatric
(including major depressive disorder, schizophrenia and addictive
disorders) or neurodegenerative (e.g. amyotrophic lateral sclerosis,
Alzheimer’s and Huntington’s diseases).
© 2019 The Authors
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S06-01
Mechanisms controlling GABAergic interneuron plasticity
in the adult brain
G. D. Cristo
University of Montreal, CHU Ste Justine Research Centre,
Montreal, Canada
Persistence of fear memories is important for survival, while the
inability to effectively adapt to trauma is characteristic of post-
traumatic stress disorder (PTSD), anxiety disorders and phobias.
Fear memories in juvenile rodents are thought to be erased
following extinction training, while extinction training only tem-
porarily and weakly suppresses fear memories in adults. The
development of GABAergic circuits, in particular of Parvalbumin-
positive (PV) cells, a GABAergic interneuron subtype innervating
hundreds of postsynaptic targets with multiple synapses clustered
around the cell body and proximal dendrites, is one of the factors
believed to restrict plasticity in the adult brain. Several recent
studies, including our own work, suggest that controlled manipu-
lation of cortical PV cell connectivity might help reinstate height-
ened plasticity in the adult brain. Our overarching goal is to
investigate the molecular mechanisms controlling PV cell plasticity
in the adult brain, since a better understanding of these mechanisms
may help develop novel tools to securely foster brain plasticity to
aid rehabilitation. Here, I will present ﬁndings showing that
reducing histone deacetylase 2 expression in PV cells increases
their plasticity and improve retention of fear extinction memories.
S06-02
Neuromodulatory control of inhibitory network
arborization in the nascent neocortex
H. Taniguchi, A. Steinecke
Max Planck Florida Institute for Neuroscience, Development and
Function of Inhibitory Neural Circuits, Jupiter, USA
Subcortical neuromodulatory systems project long-range axons to
the cortex where they adjust processing modes of cortical circuits to
environmental and behavioral states. Although their indispensable
functions in the adult cortex have been extensively studied, the
developmental role of neuromodulation in cortical circuit wiring
remains poorly understood. Here we show that intracellular
signaling driven by acetylcholine (ACh) derived from basal
forebrain cholinergic neurons plays a key role in establishing local,
dense inhibitory networks of neocortical chandelier cells (ChCs),
which powerfully control spike generation of excitatory principal
neurons (PNs) through innervation of their axon initial segments.
Activation of nicotinic ACh receptors (nAChRs) promotes ﬁlopodia
initiation that underlies axonal arborization. This ACh dependent
ﬁlopodia initiation is mediated through downstream low voltage
gated T-type calcium channels (T-type VGCCs) that shape transient
calcium elevation in axonal varicosities. The blockade of ACh
release from subcortical cholinergic neurons as well as genetic
deletion of nAChRs and T-type VGCCs dramatically decreases the
number of ChC axonal branches in vivo. These ﬁndings reveal a
novel role for cholinergic neuromodulation in axonal arborization of
developing ChCs and raise the possibility that the degree of
inhibition at the spike initiation sites of PNs is shaped by the activity
level of cholinergic neurons during development.
S06-03
Roles of long-lasting interactions between gabaergic
interneurons and oligodendrocyte progenitors in the
neocortex
M. C. Angulo
INSERM U1266, Institute of Psychiatry and Neuroscience of Paris
IPNP, Paris, France
Most cortical interneurons and the ﬁrst wave of oligodendrocyte
precursors (ﬁrstOPCs) arise from the same embryonic origin: the
medial ganglionic eminence (MGE) and the pre-optic area (POA).
However, ﬁrstOPCs are supposed to have completely disappeared at
posntatal day 10. Here we re-evaluated the death of ﬁrstOPCs and
tested whether its common embryonic origin with interneurons
contribute to the assembly of interneuron-OPC synaptic innervation
at postnatal stages that is known to be transient and highly structured
(Orduz et al., 2015, eLife). By using different transgenic mice, we
followed the fate and functional properties of interneurons and
ﬁrstOPCs from MGE and POA. First, we found that a small
proportion of ﬁrstOPCs survives after the second postnatal week.
Interestingly, these ﬁrstOPCs forms cell clusters with their lineage-
related interneurons with which they display an unexpected high
synaptic connectivity. Later in postnatal development, surviving
ﬁrstOPCs differentiate into mature oligodendrocytes inside these
cell clusters where they myelinate different types of neuronal ﬁbers
in vicinity of their lineage-related interneurons. These results show
that a common embryonic origin favor a speciﬁc spatial organization
and functional interaction between interneurons and surviving
ﬁrstOPCs in the postnatal neocortex. To understand the signiﬁcance
of these clusters during cortical development, we genetically
prevented the death of both MGE- and POA-derived interneurons
and ﬁrstOPCs that had not normally survived during the ﬁrst
postnatal week. We found that the aberrant survival of interneurons
and ﬁrstOPCs causes a strong decrease of interneuron-ﬁrstOPC
connectivity and a general imbalance in the total oligodendroglia
population. Therefore, the death/survival balance of interneurons
and ﬁrstOPCs is crucial for the regulation of the interneuron-
ﬁrstOPC connectivity and the entire population of oligodendroglia.
22 Journal of Neurochemistry © 2019 International Society for Neurochemistry, J. Neurochem. (2019) 150 (Suppl. 1), 13--61
© 2019 The Authors
S06-04
Morphological determinants of cortical gabaergic
interneuron myelination
S. Kushner1, J. Stedehouder1, D. Brizee1, J. Slotman2, M. Leyrer3,
D. Berson3, A. Houtsmuller2
1Erasmus MC, Psychiatry, Rotterdam, Netherlands
2Erasmus MC, Optical Imaging Center, Rotterdam, Netherlands
3Brown University, Neuroscience, Providence, United States
Cortical GABAergic fast-spiking parvalbumin-positive (PV)
interneurons are frequently myelinated with a proximally-biased
topography and account for a substantial fraction of neocortical
myelin. Conversely, somatostatin-positive (SOM) interneurons
contribute only modestly to myelin content in the cerebral cortex.
Previous studies have demonstrated that myelinating glia are
sensitive to ﬁber caliber for initiating axonal wrapping, however
the majority of studies have focused on the peripheral nervous
system or have been performed in cell culture settings. Given the
substantial differences in axonal morphology between local PV+
and SOM+ interneurons, we therefore sought to examine whether
cortical interneuron myelination might be related to axonal
morphology in vivo. We now demonstrate that segmental axonal
myelination of cortical interneurons is strongly predicted by the joint
combination of interbranch-point distance and local axon caliber in
both mouse and human neocortex. We further explored the
robustness of this model by either increasing PV+ interneuron size
with cell-type speciﬁc deletion of Tsc1 or reducing PV+ interneuron
size by cell-type speciﬁc deletion of Ube3a. In both cases, although
the frequency of myelinated segments was signiﬁcantly altered, the
joint combination of interbranch-point distance and local axon
caliber remained highly predictive of myelin topography. Lastly, we
considered regular-spiking SOM+ cells, which normally have
relatively shorter interbranch distances and thinner axon diameters
than PV+ cells, and are rarely myelinated. Enlargement of SOM+
cell size by cell type-speciﬁc deletion of Tsc1 dramatically increased
the frequency of myelinated axonal segments and with a topography
accurately predicted by the model. Together, our results suggest that
local axonal morphology is an important determinant underlying the
topography of cortical GABAergic interneuron myelination.
© 2019 The Authors
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S07-01
Subcellular localization of RNA-binding proteins for axon
growth regulation
M. Fainzilber1, E. Doron-Mandel1, I. Koppel1, Juan. A. Oses-
Prieto2, R. Kawaguchi3, O. Abraham1, I. Rishal1, S. Alber1, J.
Kadlec4, P. Jungwirth4, G. Coppola3, Alma. L. Burlingame2
1Weizmann Institute of Science, Dept. of Biomolecular Sciences,
Rehovot, Israel
2UCSF, Dept. of Pharmaceutical Chemistry, San Francisco, U.S.A.
3UCLA, Semel Institute for Neuroscience and Human Behavior, Los
Angeles, U.S.A.
4Czech Academy of Sciences, Institute of Organic Chemistry and
Biochemistry, Prague, Czechia
Nucleolin is a multifunctional RNA-binding protein (RBP) found
in the nucleus, cytoplasm and plasma membrane of the cell.
Previously we have shown that nucleolin localizes to axons through
interaction with the anterograde microtubule associated motor
kinesin-1 (Kif5) and that the complex transports a number of key
growth-regulating mRNAs including importin beta1 and mTOR.
Perturbation of nucleolin-kinesin interactions leads to reduced levels
of axonal nucleolin and its associated transcripts and enhances
neuronal growth. Here we identify the kinesin-binding domain
(KBD) in nucleolin, and show that the same domain mediates
nucleolin localization to the cell cortex and plasma membrane.
Heterozygous KBD-deletion mice reveal reduced axonal localiza-
tion of nucleolin in dorsal root ganglion (DRG) neurons and
enhanced axonal outgrowth. Homologous domains may exert
similar functions in other RNA-binding proteins. The current study
provides new mechanistic insights on subcellular localization of
RBPs, and how changes in subcellular RBP localization regulate
axon growth.
S07-02
Signaling mechanisms for regulation of protein synthesis
in axons
J. Twiss
University of South Carolina, Biological Sciences, Columbia, USA
Axons of cultured neurons contain 1000’s of different mRNAs,
and proteins synthesized in adult PNS axons have been shown to
support regeneration after injury. It is clear that axons can regulate
which proteins are generated when, but how this translational
regulation is achieved at a molecular level remains unknown. We
recently showed that mRNAs are stored in stress granule-like
structures in uninjured PNS axons (Sahoo et al. 2018). Over the ﬁrst
6 hours following axotomy, the stress granule proteins TIA1 and
G3BP1 show further increased aggregation in axons that then falls
to below na€ıve levels thereafter. Aggregated G3BP1 binds to axonal
mRNAs and attenuates their translation. Preventing G3BP1 aggre-
gation increases axonal mRNA translation and accelerates axon
growth in culture and in vivo. The fall in G3BP1 aggregation as
axons start to mount a regenerative response is accompanied by
phosphorylation of G3BP1 on Ser 149. Reineke et al. (2017)
reported that Casein kinase 2a (CK2a) could phosphorylate G3BP1
in other cellular systems. We ﬁnd that injury increases axonal CK2a
levels as G3BP1 aggregation declines at 16 hours post axotomy.
This CK2a upregulation is translation dependent and requires initial
translation of mTOR mRNA in axons. Axonal translation of CK2a
mRNA is inhibited by elevated axoplasmic Ca2+; in contrast
translation mRNAs needed for the initial injury response in axons is
increased when axoplasmic Ca2+ is elevated. Together, these data
indicate that axotomy is accompanied by sequential waves of local
mRNA translation, where we suspect that newly synthesized
proteins enable translation of subsequent mRNAs needed for
regeneration.
S07-03
The secret life of 3’UTRS in developing axons
C. Andreassi, A. Riccio
University College London, MRC Laboratory for Molecular Cell
Biology, London, United Kingdom
Understanding how cells translate extracellular cues into speciﬁc
patterns of gene expression is one of the major goals of modern
neurobiology. Neurons are cells with a complex morphology, which
maintain their cellular structure through the compartmentalized
expression of proteins essential for growth and plasticity. Asym-
metric localization of RNA is an evolutionarily conserved mecha-
nism that allows spatial restriction of protein synthesis to speciﬁc
cellular compartments. Incorrect processing and delivery of mRNA
causes developmental defects and severe human neurological
disorders. In neurons, mRNA transcripts are transported to both
dendrites and axons where they are rapidly translated in response to
stimuli.
This talk will explore how transcripts localized in sympathetic
neuron axons are transported, processed and translated in response
to neurotrophins. Special emphasis will be given to the nature of the
3’UTRs of targeted axons and to the presence of unique elements
that may determine their fate. I will also discuss our important
ﬁndings indicating that the 3’UTR of localized transcripts undergo
axonal cleavage and remodelling, thereby generating mRNA
isoforms expressing a shorter 3’UTR, which are rapidly translated,
and axonally cleaved RNA fragments (acRNA) with yet unknown
function.
S07-04
Axonal BDNF/TRKB signaling endosomes regulation of
MTOR-dependent local translation and dendritic
branching in somas
F. Bronfman, G. Moya-Alvarado, N. Stuardo
Catholic University Chile, Department of Physiology, Santiago,
Chile
Brain Derived Neurotrophic Factor (BDNF) is broadly express in
different circuits of the central nervous system (CNS) and binds its
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receptors TrkB and p75 to trigger different signaling pathways
regulating dendritic growth and synaptic plasticity. When binding to
BDNF, TrkB and p75 are endocytosed to signaling endosomes, that
are organelles transmitting trophic signals. Whether BDNF-TrkB-
p75 signaling endosomes in axons are regulating long-distance
signaling to cell bodies to modify neuronal morphology is unknown.
Here, we studied the functional role of BDNF-TrkB-p75 signaling
endosomes and BDNF signaling pathways in long-distance regula-
tion of dendritic growth using compartmentalized cultures of rat and
mouse cortical neurons derived from p75 knock out or TrkBF616A
knock-in mice. By applying BDNF to distal axons we showed the
capacity of axonal BDNF to increase dendrites, to activate the
transcription factor CREB in the nucleus and the PI3K-mTOR
pathway in cell bodies increasing somatodendritic protein synthesis.
TrkB activation and not p75 was required for this effect. Locally in
axons, increased activity of PLC-gamma and calcium was required
for long-distance signaling; in addition to Rab5 (early endosomes
regulator) and dynein activities. Our results suggest a compartmen-
talized activation of BDNF signaling pathways in axons and
dendrites a role of BDNF-TrkB signaling endosomes in coordinat-
ing this process as well as wiring of circuits in the CNS.
© 2019 The Authors
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S08 The NMDA receptors: from synapse physiolgy to pathology
S08-01
The NMDA receptor co-agonist D-serine is essential for
dopamine modulations of prefrontal neuronal activity and
cognitive function
J.-P. Mothet
CNRS - ENS Paris Saclay, Laboratoire Aime Cotton, UMR9188,
Orsay, France
Dopaminergic modulation of glutamatergic neurotransmission in
the prefrontal cortex (PFC) plays an important role in the control of
cognitive functions. Accordingly, disruption of frontocortical
dopamine(DA)-glutamate cross-talk is a hallmark of several
neuropsychiatric disorders, including schizophrenia. In addition,
hypoactivity of NMDA receptors (NMDAR) due to reduced
availability of their co-agonist D-serine is implicated in schizophre-
nia. Whether dopaminergic modulations of neuronal activity and
cognitive functions involve D-serine is not known. Herein, we show
that pharmacologically- and genetically-driven depletions of D-
serine impair positive and negative modulations of glutamatergic
transmission, neuronal excitability and plasticity by D1 and D3-
receptor activation, respectively. Furthermore, we report that the
selective blockade of the D3-receptors increases global PFC activity
and cognition in wild-type but not in null-mutant mice for serine
racemase the enzyme that synthesizes D-serine. All these aberrant
physiological and behavioral signatures found in the mutant mice
were fully alleviated by chronic treatment of the mice with D-serine.
Finally, we reveal that D1R and D3R activations coordinately
regulate in opposite directions the extracellular levels of D-serine in
the PFC and identify the cAMP/PKA pathway as a molecular hub
through which DAergic receptors control the activity of the co-
agonist at NMDARs. Collectively, our results reveal a key role for
D-serine in the healthy neuromodulation by DA of PFC activity,
ﬁndings highly relevant to the etiology and treatment of schizophre-
nia but also to disease where the dopamine-glutamate cross-talk is
disrupted
S08-02
Glutamate is required for depression but not potentiation
of long-term presynaptic function
N. Empage
University of Oxford, Pharmacology, Oxford, United Kingdom
High-resolution ﬂuorescence imaging of synaptic transmission,
performed in living mammalian brain tissue, reveal data that offer a
robust counterpoint to a widely held view that central synapse
plasticity occurs exclusively at the post-synaptic locus. A meta-
analysis of the plasticity literature offered a conceptually signiﬁcant
thread that has lead us to an experimental demonstration that
glutamate functions to depress its own release at central synapses
during Hebbian plasticity. The mechanistic basis of this form of
plasticity has been explored using the optical quantal analysis
technique to reveal that it is critically dependent upon glutamate’s
interaction with presynaptic NMDA receptors. This surprising result
is likely to be of some importance, as it underscores the unique
signiﬁcance of presynaptic plasticity in synaptic transmission.
S08-03
NMDA receptor C-terminal domain signaling in health and
disease
G. Hardingham
University of Edinburgh, UK Dementia Research Institute,
Edinburgh, United Kingdom
The GluN2 subtype (2A vs. 2B) determines key biophysical
properties of forebrain NMDA receptors. During development,
GluN2A becomes incorporated into previously Glu2NB-dominated
NMDARs, but both are highly expressed in the adult forebrain. In
addition to controlling channel properties, GluN2A and GluN2B
have large and highly divergent cytoplasmic C-terminal domains.
Using genetically modiﬁed mice with targeted mutation of exchange
of GluN2 C-terminal domains, we are investigating their role in
development and disease. Key questions include their role in
directing the switch in NMDA receptor subunit composition, and in
pro-death signaling in acute and chronic neurological conditions.
References:
Martel et al (2012) Neuron; Hardingham & Do (2016) Nat. Rev.
Neuro; McQueen et al (2017) ELife; McKay et al (2018) Cell
Rep.
S08-04
Metabotropic NMDA receptor signaling underlies beta-
amyloid induced synaptic dysfunction
K. Dore
UCSD, Neurosciences, La Jolla, USA
Until recently, NMDA receptor (NMDAR) functions have been
attributed to its ability to conduct calcium ions. However, growing
evidence demonstrates that the NMDAR can induce synaptic
depression without ion-ﬂux, suggesting that is has a metabotropic
function. Our results show that glutamate binding or elevated
amounts of beta-amyloid can trigger a conformational change in the
NMDAR c-terminal domain. We have shown previously that this
movement affects interactions between the NMDAR and signaling
molecules, which results in synaptic depression. PSD-95, a major
scaffolding protein at the synapse, binds directly to NMDARs and is
signiﬁcantly depleted in neurons exposed to beta-amyloid as well as
in brain tissue of patients with Alzheimer’s disease. In this talk, we
will focus on recent experiments showing that increased PSD-95 can
block metabotropic NMDAR signaling and thus prevent synaptic
weakening induced by beta-amyloid. Our results show that large
spines, containing increased amounts of endogenous PSD-95 have a
similar NMDAR conformation as spines not exposed to beta-
amyloid. Also, beta-amyloid overexpression speciﬁcally reduced
PSD-95 content in small spines, leaving larger spines unaffected.
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Moreover, overexpressed PSD-95 does not potentiate synaptic
transmission in tissue lacking the AMPA receptor subunit GluA1
while elevated PSD-95 still blocks beta-amyloid-induced synaptic
depression in GluA1-lacking tissue. These results indicate that PSD-
95 rescue of beta-amyloid induced depression is not due to synaptic
potentiation but by a blockade of NMDAR metabotropic signaling.
We are now testing a pharmacological approach to increase synaptic
PSD-95 in vitro and in APP/PS1 model mice. Preliminary
experiments suggest that this approach could lead to a possible
new treatment against Alzheimer’s.
© 2019 The Authors
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S09 Neuroprotection through Autophagy: the next milestones
S09-01
The molecular interplay between autophagy and
proteasome in motoneuron diseases
A. Poletti, R. Cristofani, P. Rusmini, V. Crippa, M. E. Cicardi, V.
Ferrari, B. Tedesco, M. Piccolella, M. Galbiati, E. Messi
Universita degli Studi di Milano, Center of Excellence on
Neurodegenerative Deseases, Milano, Italy
Several adult onset motoneuron diseases (MNDs) are linked to
the presence of misfolded proteins which aberrantly behave in
affected cells perturbing the normal cell functions. Amyotrophic
lateral sclerosis (ALS) is a typical MNDs associated with misfolded
proteins. We studies how these MNDs-proteins accumulate into
aggregates during disease showing that they are typically poorly
removed by, or may impair, the protein quality control (PQC)
system. The PQC system is composed of chaperones and degrada-
tive pathways (proteasome and autophagy). We found that the
potentiation of the chaperone-assisted selective autophagy (CASA)
is sufﬁcient to clear aggregated misfolded species. CASA relies of
the CASA complex formed by the small heat shock protein B8
(HSPB8) its co-chaperone BAG3, the chaperone HSC70 and the E3-
ubiquitin ligase CHIP. The CASA complex recognizes and ubiq-
uitinated misfolded proteins for the insertion into autophagosomes.
Notably, HSPB8 overexpression is sufﬁcient to improve CASA
complex activity and aggregate clearance, while is downregulation
has the opposite effect. We found that the inhibition of CASA
complex correlates with the activation of an alternative co-
chaperone, BAG1, which sequesters HSC70/CHIP from the CASA
complex, routing misfolded proteins to proteasome for degradation.
Any alteration of this ﬁne equilibrium results in misfolded protein
accumulation. We thus postulated that when misfolded proteins are
poorly transported to degradation by autophagy or stored in
aggresome, the cells activate a compensatory mechanism based on
BAG1 to target the HSC70-bound cargo to the proteasome in a
active transport-independent manner.
S09-02
Selective autophagy: ﬁghting neurodegeneration one
protein at a time
A. M. Cuervo
Albert Einstein College of Medicine, Institute for Aging Studies, The
Bronx, USA
Cells count on surveillance systems to handle protein alterations
and organelle damage. Malfunctioning of these systems occurs with
age and is on the basis of different neurodegenerative conditions.
Our studies have focused primarily on autophagy. We have found a
double interplay whereby, different autophagic pathways contribute
to clearance of pathogenic proteins but, conversely, these pathogenic
proteins often became toxic for the autophagic system. Our current
efforts are oriented to investigate the consequences of this toxicity
on two selective forms of autophagy, chaperone-mediated autop-
hagy (CMA) and in endosomal-microautophagy. We have devel-
oped conditional mouse models with modulatable CMA, where we
have identiﬁed that decline on CMA activity contributes to
neurodegeneration, increases proteotoxicity, accelerates the course
of disease and facilitates propagation of the proteotoxic signature.
We are currently utilizing genetic and chemical approaches to
upregulate CMA in the neurodegenerative setting to determine the
possible therapeutic value of such intervention.
S09-03
Autophagy in neurons: from development to degeneration
P. Boya
CIB, CSIC, Madrid, Spain
Autophagy is an essential intracellular degradation pathway that
recycles cell components, thereby generating new building blocks
and energy to maintain cellular homeostasis. Autophagy plays an
important part in the response to nutrient starvation and the
recycling of damaged organelles, and serves as a key survival
mechanism in conditions of stress. Our group has shown that
autophagy is necessary for neuronal differentiation and for the
removal of apoptotic cells during normal development of the
nervous system. Furthermore, our ﬁndings suggest a metabolic role
of autophagy, which may enable the production of ATP through the
degradation of cellular components. We have recently demonstrated
that mitophagy (the selective degradation of mitochondria) regulates
metabolic reprogramming that is essential for neuronal differenti-
ation. We are also exploring how autophagy defects are associated
with age-related diseases such as glaucoma and Parkinson’s disease
and whether manipulation of this process could represent new
therapeutic strategies for neurodegenerative conditions.
S09-04
Alterations in RAB-mediated membrane trafﬁcking in
neurological disease
P. McPherson
Montreal Neurological Institute, McGill University, Neurology and
Neurosurgery, Montreal, Canada
Membrane trafﬁcking controls the levels and localization of
proteins, and thus cellular function, and alterations in trafﬁcking
pathways contribute to human disease. Rab GTPases are key
switches turning trafﬁcking on and off. Our discovery that the
differentially expressed in normal and neoplastic cells (DENN)
domain functions enzymatically as a guanine-nucleotide exchange
factor (GEF) to activate Rabs provided new understanding in the
regulation of Rabs in membrane trafﬁcking. There are 26 DENN
domain (DENND) proteins in humans making them a critical new
class of trafﬁcking regulators. Here I will describe how alterations in
DENN domain proteins and their Rab substrates contribute to
neurological disease. Speciﬁcally I will discuss the role of DENND1
and its substrate Rab35 in the development of brain tumors and our
recent discovery that mutations in DENND5A cause a severe
neurodevelopmental disorder called epileptic encephalopathy.
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S10 Insights on organoid and 3D models to study brain diseases and
development
S10-01
Modelling human brain developmental diseases using on-
chip human brain organoids
O. Reiner, R. Y. Tshuva
Weizmann Institute of Science, Molecular Genetics, Rehovot, Israel
Human brain folding has been implicated in neurodevelopmental
disorders such as lissencephaly. Here, we will describe using our on-
chip human brain organoid platform to study the appearance of
surface folds during the in vitro development and self-organization.
Our micro-fabricated devices supports in situ imaging over a
timescale of weeks. Lissencephalic (smooth brain) organoids display
reduced convolutions, modiﬁed scaling and a reduced elastic
modulus. Whereas we could also observe size reduction in
microcephalic brain organoids. Our on-chip approach offers a
means for studying the emergent properties of organoid develop-
ment, with implications for the embryonic human brain.
S10-02
Using human cerebral organoids to probe the
consequences of rare highly-penetrant mutations in major
mental illness
M. Johnstone
University of Edinburgh, Division of Psychiatry, Edinburgh, United
Kingdom
Schizophrenia and other major mental illnesses including classic
neurodevelopmental disorders are highly heritable. Large-scale
studies have shown that genomic variation, in the form of copy
number variants (CNVs), accounts for a signiﬁcant portion of risk.
CNVs in the disrupted in schizophrenia 1 (DISC1)-interactor and
nuclear distribution factor E-homolog 1 gene (NDE1) on chromo-
some 16q13.11, that lead to SCZ and neurodevelopmental disorders
are proposed to result in abnormal neuronal precursor cell (NPC)
proliferation and differentiation. Our group has tested this hypoth-
esis by generating a platform of human iPSCs from patients with
schizophrenia, and other neurodevelopmental disorders, who are
known to have CNVs affecting NDE1. We have differentiated these
iPSCs into NPCs in vitro and have undertaken comparative studies
between mutant and control cell lines. In parallel we have also
studied the effects of NDE1 on developmental pathways in ‘cerebral
organoids’; a three-dimensional tissue culture of human iPSC that
mimics early stages of human cortical development. Studying
neurodevelopmental disorders in three-dimensional in vitro cultures
can teach us fundamental aspects of the development of the human
cortex, that are beyond reach in current animal model systems.
Human brain imaging of affected carriers of the 16p13.11
microduplication showed reduced brain volume. IPSC-derived brain
organoids from these patients were smaller and showed reduced
neuronal progenitor cell proliferation. Transcriptomic and proteomic
data shows deﬁcits in key intracellular signaling pathways
associated with proliferation which we have been able to rescue
both genetically and pharmacologically. This study shows as a
proof-of-principle that cerebral organoid technology holds much
promise to probe the mechanistic underpinnings of neurodevelop-
mental and neuropsychiatric disorders.
S10-03
Genetic evolution of cerebral cortex size and folding
V. Borrell
Consejo Superior de Investigaciones Cientıﬁcas, Institute of
Neuroscience, San Juan de Alicante, Spain
One of the most prominent features of the human brain is the
fabulous size and folding of the cerebral cortex, which emerge
during development. Cortex size is determined by neurogenesis. We
have found that direct neurogenesis from Radial Glia Cells (RGCs),
with limited neuron production, dominates the avian, reptilian and
mammalian paleocortex, whereas in the evolutionarily recent
mammalian neocortex most neurogenesis is indirect via intermediate
progenitors. Our experiments in mouse, chick and snake embryos,
and human cerebral organoids, demonstrate that Slit/Robo signaling
is necessary and sufﬁcient to drive direct neurogenesis. Attenuating
Robo signaling in snakes and birds promotes the formation of
intermediate progenitors and indirect neurogenesis, as in mammals.
Further expansion and folding of the mammalian neocortex depends
on the abundance of basal RGCs found in a unique germinal layer,
the Outer Subventricular Zone (OSVZ). We have found that during
a brief developmental period, RGCs in the ventricular zone generate
a burst of bRGCs that become founders of the OSVZ, after which
they follow a lineage completely independent from other germinal
zones. This brief period is conﬁned by the dynamic temporal
regulation of genes key for bRGC formation, determining the
emergence of the OSVZ and folding of the cortex. Cortex folding
occurs in highly stereotyped patterns, and we have identiﬁed unique
transcriptional signatures along germinal zones of the human and
ferret cortex, but not mouse, mapping the prospective location of
folds and ﬁssures. These include genes mutated in human cortical
malformations, and may deﬁne cortical folding patterns. Our studies
identify modulation in expression and activity levels of conserved
signaling pathways as a primary mechanism driving the expansion,
folding and increased complexity of the mammalian neocortex
during evolution.
© 2019 The Authors
Journal of Neurochemistry © 2019 International Society for Neurochemistry J. Neurochem. (2019) 150 (Suppl. 1), 13--61 29
S10-04
LGALS3BP modulates local gyriﬁcation in the human
brain
C. Kyrousi
Max Planck Institute of Psychiatry, Department of Developmental
Neurobiology, Munich, Germany
Basal radial glial cells (bRGs) are a neural progenitor type
enriched in primates and humans and conto the expansion of
neugenerated during cortical dein gyrencephalic species. Shortly
after their generation, bRGs delaminate towards the outer subven-
tricular zone, where they divide multitimes before terminal diffe The
reguof bRGs generation is essential for the establishment of correct
gyriﬁcation within the human cortex. Here, we study the role of
LGALS3BP, a secreted prowhose RNA exis enriched in bRGs. By
using cerebral organoids, human fetal tissues and mice, we show
that manipulation of LGALS3BP regubRG generation. Ad indivi-
duals with unique de novo variants in LGALS3BP demonabnormal
gyriﬁcation and thickness at multisites over the cerebral cortex.
Single-cell-RNA-sequencing reveals the extracellular matrix invol-
vement in the LGALS3BP mediated mecha We ﬁnd that
LGALS3BP is required for bRGs delamination and inﬂuences
cortical deand gyriﬁcation in humans.
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S10 Insights on organoid and 3D models to study brain diseases and development
S11 Neuron-Glia signaling in synaptic plasticity: Astrocytes Rule!
S11-01
Astrocytes as key drivers in NMDA receptor-depedent
long term depression
M. Navarrete
Instituto Cajal, CSIC, Functional and Systems Neurobiology
department, Madrid, Spain
Astrocytes are increasingly being recognized as active players for
neuronal synaptic communication, with multiple functions for
central nervous system physiology. Nevertheless, astrocytes are
typically considered as modulators of core mechanisms driven by
the neuronal components, or are thought to provide metabolic ﬁne-
tuning for neuronal function (for instance by regulating neurovas-
cular-neuroenergetic coupling). We will discuss new conclusive
evidences that challenge this view, speciﬁcally for a form of
synaptic plasticity involved in cognitive function: NMDA receptor-
dependent long-term depression (LTD) in the hippocampus. Even
though the molecular mechanisms for LTD are still being
elucidated, the basic sequence of events that leads to synaptic
depression appears to be well established (and widely accepted):
prolonged, low-frequency release of glutamate from the presynaptic
terminal, activation of postsynaptic NMDA receptors and engage-
ment of speciﬁc signaling cascades that lead to the removal of
AMPA receptors from the postsynaptic membrane. I will present a
fundamental change of paradigm, in which the axis composed of
presynaptic neuron-astrocyte-postsynaptic neuron deﬁnes an obli-
gatory relay for information processing leading to synaptic plastic-
ity.
S11-02
Signaling of CB1 receptors in astrocytes
G. Marsicano
INSERM U1215, Neurocentre Magendie, Bordeaux cedex, France
Type 1 cannabinoid receptors (CB1) are expressed at very low
levels in astrocytes as compared to other brain cell types. However,
they play key roles in speciﬁc responses to cannabinoid drugs and in
the ﬁne physiological regulation of behavior. In this presentation, I
will go through our studies on the functions exerted by astroglial
CB1 receptors in the brain, ranging from the control of synaptic
plasticity, the regulation of learning and memory and the partici-
pation in key bioenergetic processes.
S11-03
The involvement of astrocytes in cognitive processing
J. Oliveira1,2,3
1Life and Health Sciences Research Institute ICVS, School of
Medicine, University of Minho, ICVS, Braga, Portugal
2ICVS/3B’s - PT Government Associate Laboratory, ICVS, Braga,
Portugal
3IPCA-EST-2Ai, Polytechnic Institute of Cavado and Ave, Applied
Artiﬁcial Intelligence Laboratory, 2Ai, Barcelos, Portugal
Astrocytes interact with neurons at the cellular level through
modulation of synaptic formation, maturation, and function, but the
impact of such interaction in circuit activity that results in behavior
remains unclear. Here, we studied the mouse models with impaired
exocytosis in astrocytes to dissect the role of astrocyte-derived
signaling in cortico-hippocampal circuits, with implications for
cognitive processing. We found that the blockade of gliotransmitter
release in astrocytes triggers a critical desynchronization of neural
theta oscillations between the dorsal hippocampus and prefrontal
cortex. Moreover, we found a strong cognitive impairment in tasks
depending on this network. In this talk, I will discuss also further
evidence suggesting the involvement of astrocyte-released signals in
mechanisms of long-distance network modulation, with direct
implications to cognitive function.
S11-04
Astrocyte signalling control of spike timing-dependent
plasticity
A. Rodriguez-Moreno
Universidad Pablo de Olavide, Departamento de Fisiologıa,
Anatomıa y Biologıa Celular, Sevilla, Spain
Critical periods of synaptic plasticity facilitate the reordering and
reﬁning of neural connections during development, allowing the
deﬁnitive synaptic circuits responsible for correct adult physiology
to be established. Presynaptic spike timing-dependent long-term
depression (t-LTD) exists in the hippocampus, which depends on
the activation of NMDARs and that probably fulﬁlls a role in
synaptic reﬁnement. This t-LTD is present until the 3rd postnatal
week in mice, disappearing in the 4th week of postnatal develop-
ment. We were interested in the mechanisms underlying this
maturation related loss of t-LTD and we found that at CA3-CA1
synapses, presynaptic NMDA receptors (preNMDARs) are tonically
active between P13 and P21, mediating an increase in glutamate
release during this critical period of plasticity. Conversely, at the end
of this critical period (P22-P30) and coinciding with the loss of t-
LTD, these preNMDARs are no longer tonically active. Using
immunogold electron microscopy, we demonstrated the existence of
preNMDARs at Schaffer collateral synaptic boutons, where a
decrease in the number of preNMDARs during development
coincides with the loss of both tonic preNMDAR activation and t-
LTD. Interestingly, this t-LTD can be completely recovered by
antagonizing adenosine type 1 receptors (A1R), which also recovers
the tonic activation of preNMDARs at P22-P30. By contrast, the
© 2019 The Authors
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induction of t-LTD was prevented at P13-P21 by an agonist of A1R,
as was tonic preNMDAR activation. Furthermore, we found that the
adenosine that mediated the loss of t-LTD during the fourth week of
development is supplied by astrocytes. These results provide direct
evidence for the mechanism that closes the window of plasticity
associated with t-LTD, revealing novel events probably involved in
synaptic remodeling during development.
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S12 ASN Folch-Pi Award Symposium - Lipidomics as a tool to study
metabolic and environmental contributors to Alzheimer’s Disease
S12-01
Lipidomic characterization of pro-repair lipid pathways in
Alzheimer’s Disease
A. Taha
University of California - Davis, Food Science and Technology,
Davis, USA
Background: Alzheimer’s Disease (AD) is a progressive brain
disorder characterized by persistent inﬂammation and neuronal
damage. Specialized lipid mediators known to resolve neuroinﬂam-
mation and repair damaged neurons have been reported to be
reduced in post-mortem brains of AD patients. However, the
underlying cause of this reduction is not known.
Hypothesis and objective: The present study tested the hypoth-
esis that pathways regulating pro-repair lipid mediator metabolism
are altered in post-mortem brains of AD patients.
Methods: Post-mortem pre-frontal cortex from pathologically
conﬁrmed AD subjects (n=21) and unaffected controls (n=20) was
subjected to lipidomic analysis with ultra-high pressure liquid
chromatography coupled to tandem mass-spectrometry following
separation of brain esteriﬁed and unesteriﬁed lipid pools with solid
phase extraction.
Results: Compared to controls, concentrations of several pro-
repair lipid mediators esteriﬁed to neutral lipids were signiﬁcantly
reduced by ~50% in AD patients (P<0.05). No signiﬁcant changes
were observed in free or phospholipid-bound pro-repair lipid
mediators.
Conclusion: This study provides novel evidence of reduced
esteriﬁed pro-repair lipid mediators in post-mortem AD pre-frontal
cortex. Targeting pro-repair lipid mediator turnover within neutral
lipids may stimulate neuronal repair and resolution of inﬂammation
in AD.
S12-02
Chronic exposure to real-time trafﬁc related air pollution
increases neuroinﬂammation and plaque burden in
TGF344-ad rats
K. Patten1, A. E. Valenzuela1, A. Y. Taha2, K. J. Bein3,4, A. S.
Wexler3,5, P. J. Lein1
1UC Davis, Molecular Biosciences, Davis, USA
2UC Davis, Food Science and Technology, Davis, USA
3UC Davis, Air Quality Research Center, Davis, USA
4UC Davis, Center for Health and the Environment, Davis, USA
5UC Davis College of Engineering, Mechanical and Aerospace
Engineering, Civil and Environmental Engineering, Davis, USA
Epidemiological studies have linked trafﬁc-related air pollution
(TRAP) to increased risk of Alzheimer’s disease (AD). However,
this association has yet to be conﬁrmed in a preclinical model.
Moreover, the mechanism(s) by which TRAP inﬂuences AD are
unclear. To address these issues, we exposed male and female
TgF344-AD rats and congenic controls to real-time TRAP or ﬁltered
air over the course of 15 months, using a mobile exposure facility
that samples air from a highway tunnel in the Bay Area of
California. Rats were exposed to TRAP or FA from postnatal day 28
to 15 months of age. At 3, 6, 10, and 15 months of age, brain
samples were collected, and analyzed for plaque burden, bioactive
lipids, microgliosis, astrogliosis, and cytokine protein levels.
Chronic TRAP exposure increased plaque burden in AD transgenic
rats at 6 months. In addition, we found that TRAP exposure
increased pro-inﬂammatory cytokines as early as 3 months of age,
and modulated levels of both pro- and anti-inﬂammatory cytokines
at later time points. Finally, both microgliosis and astrogliosis were
increased by TRAP exposure. These data suggest that TRAP may
exacerbate AD-relevant phenotypes, and that these results may be
mediated through neuroinﬂammation. Supported by the NIEHS
(grants R21 ES025570, P30 ES023513 and T32 ES007059) and
NIA (grant P30AG010129).
S12-03
Determining blood and brain bioavailability of omega-3
fatty acids in APOE4 carriers
M. Plourde
Universite de Sherbrooke, Medecine, Sherbrooke, Canada
Approximately 20% of Canadians carry at least one epsilon 4
allele of apolipoprotein E (E4) allele, which almost doubles their
risk of late-onset Alzheimer’s disease (AD). AD risk is closely
linked to changes in lipid metabolism and there are evidences that
docosahexaenoic acid (DHA) may exert a preventive effect in AD
and that higher DHA levels in the blood is associated with better
cognition. The suggested mechanism of this link is that DHA is
more available to be taken up by the brain to fulﬁll brain DHA
turnover. However, this mechanism relies on efﬁcient DHA
transport across the blood brain barrier (BBB) and there are two
conditions to achieve that:
1) Plasma DHA is packaged in the right compartments and is
available to the brain for its uptake.
2) There are enough brain transporters at the BBB interface, such
as MFSD2A to increase DHA concentrations within the central
nervous system.
However, the apoE4 protein has lower afﬁnity for the LDL
receptor and VLDL remains for a longer period in their blood
compared to non-carriers. This means that, in E4 carriers, DHA is
probably packed more in triglycerides than to another compartment,
hence promoting its b-oxidation instead of its incorporation in
membrane and tissues. Metabolic defects in fatty acid packaging in
the blood may accentuate how much vulnerable E4 carriers are to
brain DHA deﬁciency during aging. There is no cure to AD and
hence, a reduction of even 10% in the prevalence of AD, by
providing innovative supplements, would markedly improve the
quality of life of affected Canadians, especially the 3.6 million E4
carriers aged between 30-60 years old.
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S12-04
Serum soluble epoxide hydrolase derived oxylipins as
cognitive biomarkers related to cerebral small vessel
disease and mixed alzhe
W. Swardfager1, D. Yu1,2,4, M. Hennebelle5, J. Ramirez1,3,4, P. C.
Chan6,7, A. Y. Taha5, J. Pettersen8, N. Herrmann1, K. L. Lancto^t1,2,
M. Masellis1,9, D. J. Sahlas10, S. E. Black1,9,10
1Sunnybrook Health Sciences Centre, University of Toronto, Hurvitz
Brain Sciences Research Program, Toronto, Canada
2University of Toronto, Department of Pharmacology & Toxicology,
Toronto, Canada
3Heart and Stroke Foundation, Canadian Partnership for Stroke
Recovery, Sunnybrook RI, Toronto, Canada
4Sunnybrook Research Institute, LC Campbell Cognitive Neurology
Research Unit, Toronto, Canada
5University of California, Department of Food Science and
Technology, College of Agriculture and Environmental Sciences,
California, USA
6Sunnybrook Health Sciences Centre, Department of Clinical
Pathology, Toronto, Canada
7University of Toronto, Department of Laboratory Medicine and
Pathobiology, Toronto, Canada
8Sunnybrook HSC, Department of Medicine (Neurology, Toronto,
Canada
9McMaster University, Department of Medicine (Neurology,
Toronto, Canada
10Toronto Rehabilitation Institute, University Health Network,
Toronto, Canada
Background: Cerebral small vessel disease is commonly
comorbid with late-onset Alzheimer’s disease (AD). The soluble
epoxide hydrolase (sEH) enzyme inactivates anti-inﬂammatory and
vasoactive cytochrome p450 derived polyunsaturated fatty acid
epoxides by converting them into cytotoxic dihydroxy oxylipin
species. Here we investigate serum concentrations of the sEH-
derived dihydroxy species and their parent epoxides as correlates of
cerebral small vessel disease and the related cognitive deﬁcits in
patients with and without AD.
Methods: The present study included participants with AD and
cognitively healthy elderly controls, each separated into groups with
either extensive or minimal small vessel disease as determined by
visual rating of white matter hyperintensities on multimodal 3.0 T
MRI. The oxylipins were extracted from serum using solid phase
extraction, then quantiﬁed with a targeted ultrahigh pressure liquid
chromatography mass spectrometry (UPLC-MS/MS) lipidomics
platform. A unit-weighted composite Z-score of speed, attention
and executive function was derived from age, gender and education
corrected norms from the Digit Symbol Substitution Test, Trial-
Making Test Part B, Stroop Color-Word Interference Test, and FAS
Verbal Fluency Test. Memory was assessed using the California
Verbal Memory Test, 2nd Edition. Multivariate analyses of
covariance, and linear regression models, were used to investigate
the association between the oxylipins and white matter hyperinten-
sities and cognitive performance, respectively.
Results: Preliminary data included 30 participants with AD and
54 participants without AD. The serum concentration of 12,13-
dihydroxyoctadecamonoenoic acid (12,13-DiHOME; an sEH
derived linoleic acid oxylipin) relative to its epoxide sEH substrate
12,13-epoxyoctadecenoic acid (12,13-EpOME) was higher among
patients with extensive small vessel disease. The 12,13-DiHOME/
12,13-EpOME ratio was negatively associated with a composite
score of executive function, processing speed, and attention in all
participants with extensive small vessel disease, including sub-
groups with AD and without AD. The ratio was not related to
memory performance. Replication is now underway in a larger
sample.
Conclusions: Oxylipins derived from sEH activity were associ-
ated with a cognitive proﬁle consistent with vascular cognitive
impairment. A putative linoleic acid-derived biomarker appears to
be relevant to cognition in elderly people with extensive cerebral
small vessel disease, both with and without dementia due to
concomitant Alzheimer’s disease.
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S13 Emerging biomarker concepts in neurodegenerative diseases
S13-01
The value of a-synuclein as a diagnostic or prognostic
biomarker
M. B€ahr
Georg-August Universit€at G€ottingen, Neurology, G€ottingen,
Germany
In Neurodegenerative Disorders there is a wide ﬁeld of recent and
ongoing search for useful biomarkers for early and differential
diagnosis, disease monitoring or subtype characterization. Cere-
brospinal ﬂuid (CSF) is often used as a source for biomarker
development in different neurological disorders because it reﬂects
changes in central-nervous system homeostasis. The presentation
gives an overview about different biomarker approaches, mainly
focusing on CSF analyses. Current state and future perspectives
regarding classical protein markers, but also different “omics”
techniques are described. In conclusion, technical advancements in
the ﬁeld already yielded promising results, but further multicenter
trials with well-deﬁned cohorts, standardized protocols and inte-
grated data analysis of different modalities are needed before
successful translation into routine clinical application.
S13-02
From biomarkers to clinical studies
J. Schulz1,2
1RWTH Aachen, Dept of Neurology, Aachen, Germany
2JARA-Brain Institute Molecular Neuroscience and Neuroimaging,
FZ J€ulich, J€ulich/Aachen, Germany
Most neurodegenerative disorders, including the hereditary
forms, are slowly progressive. The functional decline is measured
with validated clinical scales that reﬂect the impairment of the
patients. The slow progression of the functional impairment, the
day-to-day variation of patients performing the scales, as well as the
interpretation by the observers require large patient numbers and
long trial durations in order to reveal an effect of disease-modifying
interventions. Molecular biomarkers, which reﬂect the pathophys-
iology of a disorder, address the question of whether an interven-
tional treatment is on target, and may also help address the
effectiveness and the effect size of a given intervention. In
neurodegenerative diseases it has also been shown that magnetic
resonance imaging (MRI) is sufﬁciently sensible to measure focal
atrophy before patients become symptomatic, and to measure
volume loss more sensibly than clinical scales can detect functional
deterioration1.
I will use Friedreich ataxia as an example for the use of
biomarkers. Friedreich ataxia is autosomal-recessively inherited, the
most prevalent genetic form of ataxia with a typical onset before the
age of 25 years. It is caused by a loss of Frataxin and subsequent
loss of mitochondrial dysfunction in several neuronal and non-
neuronal tissues. Epigenetic modiﬁcations, particularly HDAC
inhibition by nicotinamide, leads to an increase in Frataxin. Based
on natural history data2,3it was calculated that a clinical trial needs to
include 225 patients and a treatment period of two years to prove
efﬁcacy of the therapeutic intervention. Volumetric measurements
of the spinal cord may help substantiate the protective effect.
References:
1. Dogan I, ..Schulz JB, Reetz K. Structural characteristics of the
central nervous system in Friedreich ataxia: an in vivo spinal cord
and brain MRI study. J Neurol Neurosurg Psychiatry. 2019
May;90(5):615-617. https://doi.org/10.1136/jnnp-2018-318422.
2. Reetz K, .., Schulz JB; EFACTS Study Group. Progression
characteristics of the European Friedreich’s Ataxia Consortium
for Translational Studies (EFACTS): a 2 year cohort study.
Lancet Neurol. 2016 Dec;15(13):1346-1354. https://doi.org/10.
1016/s1474-4422(16)30287-3.
3. Reetz K, . . . Schulz JB. Biological and clinical characteristics of
the European Friedreich’s Ataxia Consortium for Translational
Studies (EFACTS) cohort: a cross-sectional analysis of baseline
data. Lancet Neurol. 2015 Feb;14(2):174-82. https://doi.org/10.
1016/s1474-4422(14)70321-7.
S13-03
Alpha-synuclein as a potential biomarker and therapeutic
target for parkinson’s disease
L. Kalia
Movement Disorders Centre, Toronto Western Hospital, University
of Toronto, Toronto, Canada
Parkinson’s disease is the most common neurodegenerative
movement disorder. Yet diagnostic biomarkers, which are measures
that detect the presence of Parkinson’s disease or identify individ-
uals with a subtype of Parkinson’s disease, remain elusive as none
are yet available or approved for clinical use. Multiple lines of
evidence support a role of the protein alpha-synuclein in the
pathophysiology of Parkinson’s disease. Hence an important focus
for the development of disease-modifying therapies is on targeting
alpha-synuclein. In parallel, major ongoing efforts to identify
diagnostic biomarkers are aimed at measuring alpha-synuclein in
peripheral tissues and bioﬂuids. This talk will review the evidence
for alpha-synuclein as a potential therapeutic target for Parkinson’s
disease, examine the necessity of diagnostic biomarkers for clinical
trials testing disease-modifying therapies, and discuss the possible
pitfalls of a single biomarker approach for Parkinson’s disease.
S13-04
Exploration and validation of ﬂuid biomarkers in manifest
and prodromal Parkinson’s disease
B. Mollenhauer1,2
1University Medical Center Goettingen, Neurology, Goettingen,
Germany
2Paracelsus-Elena-Klinik, Movement Disorder Center, Kassel,
Germany
The causative treatment of a-synuclein (aSyn) aggregation
disorders [i.e. Parkinson’s disease (PD), multiple system atrophy
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and dementia with Lewy Bodies] is hampered by the lack of disease-
speciﬁc biomarkers to signal the risk of developing the disease
(trait), to indicate its manifestation (state), the speed of its
progression and response to therapy (rate), and to predict its clinical
course (fate).
Several cross-sectional and longitudinal single- and multicenter
cohorts of PD have been established, including the single center
DeNoPa-1 and multicenter Parkinson Progression Marker Initiative
(PPMI)2. These cohorts enable biomarker research based on clinical
phenotyping, imaging, blood/cerebrospinal ﬂuid (CSF) biomarkers
for biochemical analyses. DeNoPa also includes microbiome
studies. To study prodromal aSyn aggregation disorders people
with isolated REM sleep behaviour disorders are also recruited to
determine the evolution of biomarkers.
Several biomarkers have shown to be interesting for diagnostic
purposes of aSyn aggregation disorders, like CSF aSyn, that due to
the overlap of single values and the lack of longitudinal change has
limited clinical utility. Other biomarker (like neuroﬁlament light
chain; NfL) and other technologies (like PMCA or RT-QuIC) show
promising results. CSF NfL discriminated PD from other (atypical)
Parkinson’s syndromes, but also metabolomic and microbiome
analyses reveal interesting results as biomarker, but also to
understand the pathophysiology of the disease.
Due to the clinical heterogeneity of aSyn disorders, a multimodal
panel of different biomarkers is needed for clinical practice and as
outcome measure. Newer biomarker will have to be identiﬁed and
explored, including inﬂammatory response and including several
cross-omics approaches.
1. Mollenhauer B, Zimmermann J, Sixel-Doring F, et al.
Monitoring of 30 marker candidates in early Parkinson disease as
progression markers. Neurology 2016; 87(2): 168-77.
2. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longi-
tudinal CSF biomarkers in early Parkinson’s disease, prodromal PD
and healthy controls. Movement Disorders in press 2019.
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S14 Glial phagocytic clearance in health and disease
S14-01
Clearing the corpses: are microglia eating enough in the
diseased brain?
A. Sierra
Achucarro Basque Center Neuroscience, Glial Cell Biology Lab,
Leioa, Spain
Microglia are the brain professional phagocytes, equipped with
sensors to detect the apoptotic cell debris generated during
development, in adult neurogenic niches as well as during ageing
and neurodegenerative diseases. We will discuss recent lab ﬁndings
showing that phagocytosis goes beyond debris removal, and in fact,
it activates a coordinated transcriptional and metabolic program in
microglia that impacts on their function. We will also discuss
discus that microglial phagocytosis is very efﬁcient in physiolog-
ical conditions and that when challenged with an increasing
number of apoptotic cells, microglia plastically adapt their
behaviour and boost their phagocytic output proportionally using
different cellular strategies. In contrast, we will show that
microglial phagocytosis is impaired under pathological conditions
such as epilepsy and stroke, and discuss different cellular and
molecular mechanisms underlying this impairment. In summary,
we propose that harnessing microglial phagocytosis may serve to
control tissue damage and inﬂammation as a novel strategy to
accelerate brain recovery.
S14-02
Neuroprotective properties of the innate immune cells
S. Rivest
CHU de Quebec-Universite Laval Research Center, Neuroscience,
Quebec City, Canada
We recently found that the progressive cognitive decline and
decrease in expression of numerous synaptic markers and
neurotrophins in the brain of mouse models of Alzheimer’s
disease (AD) correlated with major changes in the proportions
of peripheral blood monocyte subsets when compared with age-
matched controls. Indeed, there is a defect in the production of
circulating M1 monocytes in APP/PS1 mice, whereas the
population of M2 monocytes remains normal in this mouse
model of AD. Injecting M-CSF to transgenic mice that
spontaneously develop AD on a weekly basis prior to the
appearance of learning and memory deﬁcits prevented cognitive
loss. The treatment also restored the population of M1
monocytes in the circulation and greatly decreased Ab levels.
In addition, M-CSF treatment resulted in the stabilization of the
cognitive decline state in transgenic mice that already had Ab
pathology. These results are quite encouraging as they suggest
that stimulating circulating monocytes may have a great
therapeutic potential for AD. It is therefore likely that stimu-
lating monocytic cells may be a new therapeutic avenue for
treating brain diseases, such as AD. In this presentation, we will
show new data regarding the potent effects of new molecules to
stimulate innate immune cells as a preventive and curative
treatment for brain diseases. We will also show the central role
of the neurovascular unit in diseases of the CNS and how it can
be targeted for novel therapeutic strategies.
The Fonds de la Recherche du Quebec – Sante (FRQS), Canadian
Institutes in Health Research (CIHR) and the Multiple Sclerosis
Scientiﬁc Research Foundation of Canada support this research.
S14-03
Brain remodeling by phagocytic astrocytes in the
penumbra region after stroke
S. Koizumi
University of Yamanashi, Department of Neuropharmacology,
Interdisciplinary Graduate School of Medicine, Yamanashi, Japan
The brain consists of neurons and much higher number of glial
cells, astrocytes, oligodendrocytes and microglia. They communi-
cate each other, by which they control brain functions. The brain is
highly vulnerable to several insults such as ischemia, but has a self-
protective and self-repairing mechanism against these, for which
glial cells have central roles. Astrocytes, the most abundant glial
cells in the brain, sense changes in brain environments, and cause
phenotypical changes dramatically, leading to unexpected regulation
of brain functions. Adult astrocytes are quiescent but become rather
reactive in response to various brain insults such as brain ischemia.
However, the functions of reactive astrocytes are poorly understood.
Here we show that astrocytes become reactive and function as a
main player of phagocytosis after transient ischemic injury in a
limited spatiotemporal pattern. After transient brain ischemia,
phagocytic astrocytes were observed within ischemic penumbra
region in the later stage of ischemia. On the contrary, phagocytic
microglia, a well-known as professional phagocytes in the brain,
were mainly observed within ischemic core region in the early stage
of ischemia. Phagocytic astrocytes upregulated ABCA1 and its
pathway molecules, MEGF10 and GULP1, which were required for
their phagocytosis. In addition, upregulation of ABCA1 was
sufﬁcient for the phagocytosis. Together, these ﬁndings suggest
that astrocytes should be transformed into phagocytic phenotype via
increasing ABCA1 and its related molecules. Judging from the
spatiotemporal pattern of the phagocytic astrocytes, they have
distinct roles from microglia, and would contribute to remodeling of
the penumbra networks.
S14-04
The role of astrocytes in accumulation and spreading of
pathogenic proteins
A. Erlandsson
Uppsala university, Department of Public Health and Caring
Sciences, Uppsala, Sweden
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are
neurodegenerative diseases, affecting a large proportion of the
elderly population. Knowledge about the cellular mechanisms
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behind the propagation of these diseases in the brain is limited.
Decades of research have focused on neuronal abnormalities in AD
and PD, but recently more attention has been given to glial cells.
The aim of our research is to clarify the involvement of astrocytes in
the progression of AD and PD and to investigate their therapeutic
potential. Our results demonstrate that astrocytes engulf large
amounts of aggregated amyloid beta (Ab) and alpha-synuclein (a-
SYN) that is stored, rather than degraded by the cells. The
accumulation of Ab/a-SYN in astrocytes results in lysosomal
defects and spreading of neurotoxic protein aggregates via tunneling
nanotubes and extracellular vesicles. Our hypothesis is that astro-
cytes try to be “helpful” by ingesting the pathogenic proteins, but
are overwhelmed by the challenge and instead promote disease
spreading and neuronal cell death. Being the most numerous glial
cell type in the brain, astrocytes constitute a compelling treatment
target. Interestingly, our recent data demonstrates that antibody
treatment effectively prevent accumulation of toxic Ab/a-SYN
aggregates in the astrocytes.
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S15 Pathophysiological mechanisms producing early onset epilepsies with
severe comorbid neurodevelopmental disorders
S15-01
Epilepsy-associated intellectual disability triggered by
abnormal interactions of ion channels with signaling
pathways
L. Kaczmarek
Yale University, Pharmacology, New Haven, USA
The KCNT1 gene encodes a sodium-activated potassium channel
termed Slack (also KNa1.1 and Slo2.1). Slack is expressed
predominantly in neurons, where it regulates excitability and
patterns of ﬁring in response to synaptic stimulation. Mutations in
KCNT1 lead to several types of early onset epilepsies, as well as to
autism. Many of these mutations are located in the large cytoplasmic
C-terminus of the protein and in, all cases, the mutations are
associated with very severe intellectual disability. Expression of the
KCNT1 mutants in heterologous cells or in human IPS-derived
neurons reveals that the disease-causing Slack channels are fully
functional but have a greater open probability than wild type
channels. This gain-of-function results in a hyperexcitable pheno-
type. To address the impact of these mutations on cellular function,
we have analyzed the interactions of the cytoplasmic C-terminus
with other cellular proteins. We have found that the channels bind to
Phactr1 (Phosphatase and Actin Regulatory Protein-1), the RNA-
binding protein FMRP (Fragile X Mental Retardation Protein), and
to CYFIP1 (Cytoplasmic FMRP-Interacting Protein-1). The two
latter proteins are known regulators of RNA-translation. Using a
ﬂuorescent reporter for mRNA translation we have found that
stimulation of Slack channels increases translation rate. This
channel-dependent translation is markedly potentiated by loss of
FMRP or by a disease-causing Slack mutant. Our results suggest
activity-dependent mRNA translation is directly linked to channel
activation and that this is impaired by such channel mutations. This
deﬁcit may underlie the intellectual disability that results from
enhanced channel activity.
S15-02
Pathophysiological mechanism of PHACTR1 mutations
causing west syndrome, an infantile epilepsy with
intellectual disability
K.-i. Nagata, N. Hamada
Institute for Developmental Research Aichi Human Service Cen,
Molecular Neurobiology, Aichi, Japan
Trio-based whole exome sequencing identiﬁed two de novo
heterozygous missense mutations [c.1449T>C/p.(Leu500Pro) and
c.1436A>T/p.(Asn479Ile)] in PHACTR1, encoding a molecule
critical for the regulation of protein phosphatase 1 (PP1) and the
actin cytoskeleton, in unrelated Japanese individuals with West
syndrome (infantile spasms with intellectual disability (ID)). We
then examined the role of Phactr1 in the development of mouse
cerebral cortex and the pathophysiological signiﬁcance of these two
mutations and others [c.1561C>T/p.(Arg521Cys) and c.1553T>A/
p.(Ile518Asn)], which had been reported in undiagnosed ID patients.
Immunoprecipitation analyses revealed that actin-binding activity of
Phactr1 was impaired by the p.Leu500Pro, p.Asn479Ile and
p.Ile518Asn mutations while the p.Arg521Cys mutation exhibited
impaired binding to PP1. Acute knockdown of mouse Phactr1 using
in utero electroporation caused defects in cortical neuron migration
during corticogenesis, which were rescued by an RNAi-resistant
Phactr1 but not by the four mutants. Experiments using knockdown
combined with expression mutants, aimed to mimic the effects of
the heterozygous mutations under conditions of haploinsufﬁciency,
suggested a dominant negative effect of the mutant allele. As for
dendritic development in vivo, only the p.Arg521Cys mutant was
determined to have dominant negative effects, because the three
other mutants appeared to be degradated with these experimental
conditions. Electrophysiological analyses revealed abnormal synap-
tic properties in Phactr1-deﬁcient excitatory cortical neurons. Our
data show that the PHACTR1 mutations may cause morphological
and functional defects in cortical neurons during brain development,
which is likely to be related to the pathophysiology of West
syndrome and other neurodevelopmental disorders.
S15-03
Mechanisms of sensory circuit hyperexcitability in mouse
models of autism
K. Huber, G. Molinaro, W. Guo, J. Gibson
UT Southwestern Medical Center, Neuroscience, Dallas, USA
Autism Spectrum Disorders (ASD) in humans is characterized by
sensory processing and sensitivity problems. In Fragile X Syndrome
(FXS), a monogenic cause of ASD and intellectual disability,
individuals display behavioral sensory hypersensitivity that is
correlated with hyperexcitable cortical activity, both at rest, and in
response to sensory stimuli such as sound, as measured with
electroencephalogram (EEG). Using the mouse model of FXS,
Fmr1 knockout (KO), we have identiﬁed hyperexcitable cortical
circuit oscillations in acute slices of either auditory or somatosen-
sory cortex. Such hyperexcitable cortical circuit oscillations are
mediated by overactive metabotropic glutamate receptor 5
(mGluR5), as a result of disrupted interactions with the synaptic
scaffolding protein Homer. I will present data on the synaptic
mechanisms of hyperexcitable cortical oscillations in Fmr1 KO
mice, as well as new data from a different mouse ASD model, where
we observe mGluR5-dependent hyperexcitable cortical oscillations,
but these effects are sex-dependent. These later results may provide
insight into sex-dependent alterations in ASD-relevant behaviors
and circuit dysfunction.
© 2019 The Authors
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S15-04
Molecular mechanisms underlying brain wiring and asd-
like behaviours
N. Dominguez-Iturza, C. Bagni
University of Lausanne, Department of Fundamental
Neurosciences, Lausanne, Switzerland
Individuals with the 15q11.2 microdeletions, which include the
CYFIP1 gene, can present with a diverse array of symptoms such as
neurobehavioral disturbances, epilepsy and psychiatric problems.
The core behavioral features and the underlying molecular mech-
anisms of this genetic condition, however, remain unclear. In brain,
CYFIP1 regulates synapse structure and plasticity by orchestrating
two processes: actin remodeling and protein synthesis. We now
show that in mice CYFIP1 haploinsufﬁciency causes deﬁcits in
functional brain connectivity and behaviour. I will discuss the
importance of our ﬁndings for other neurodevelopmental disorders.
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S15 Pathophysiological mechanisms producing early onset epilepsies with severe comorbid neurodevelopmental disorders
S16 Signaling Mechanisms in Cortical Development
S16-01
A non canonical role for proneural genes in maintaining
the neural stem cell pool
C. Schuurmans1,2,3, S. Han1,2, G. Wilkinson3, I. Faisal1,2, S.
Okawa4, S. Li3, L. Adnani1,3, V. E. Angarica4, D. Zinyk1,2,3, R.
Dixit1,3, Y. Ilnytskyy5, M. Brooks6, E. Raharjo7, D. Dennis3, F.
Malik8, J.-W. Kim6, W. Wu10, W. Rahmani7, D. Castro9, J. Chan10,
D. Kurrasch8, I. Kovalchuk5, A. Swaroop6, Ad. Sol4, J. Biernaskie7
1Sunnybrook Research Institute, Biological Sciences Platform,
Toronto, Canada
2University of Toronto, Biochemistry, Toronto, Canada
3University of Calgary, Biochemistry and Molecular Biology,
Calgary, Canada
4University of Luxembourg, Luxembourg Centre for Systems
Biomedicine, Luxembourg, Luxembourg
5University of Lethbridge, Biological Sciences, Lethbridge, Canada
6National Institutes of Health, National Eye Institute, Bethesda,
USA
7University of Calgary, Comparative Biology and Experimental
Medicine, Calgary, Canada
8University of Calgary, Medical Genetics, Calgary, Canada
9Instituto Gulbenkian de Cie^ncia, Medicine, Oeiras, Portugal
10University of Calgary, Pathology and Laboratory Medicine,
Calgary, Canada
The origins of adult neural stem cells (NSCs) has been elusive
until recently when it was shown that slow-dividing embryonic
NSCs are set aside to populate the adult NSC niche. To prospec-
tively identify embryonic NSCs marked for retention, we stratiﬁed
the neocortical NSC pool into four populations based on proneural
gene expression (negative, Neurog2+, Ascl1+, double+). Neurog2/
Ascl1 double+ NSCs cycle the slowest, accumulating in S-phase due
to the elevated expression of negative cell cycle regulators. Double+
NSCs are also uncommitted and are maintained in this state into the
postnatal period by Neurog2-Ascl1 cross-repression. We have thus
identiﬁed a novel mechanism for embryonic NSC retention
involving proneural gene cross-repression and multilineage priming.
S16-02
WNT signaling regulates key telencephalic midline
structures
S. Tole
Tata Institute of Fundamental Research, Biological Sciences,
Mumbai, India
The hippocampus is induced by Wnt signaling from a telen-
cephalic midline organizer, the cortical hem. Though the hem
expresses and secretes Wnt ligands, it does not itself display
indicators of canonical Wnt signaling, suggesting that it may not
respond to the ligands it secretes. The cortical hem produces at least
two mature cell types, the Cajal-Retzius neurons and the non-
neuronal choroid plexus epithelium. We examined the cortical hem
and its lineage in the context of either loss of function or constitutive
activation of b-catenin, a key component of canonical Wnt
signaling. Both perturbations cause distinct cell-autonomous and
non-cell-autonomous disruptions of midline patterning. Together,
our results indicate that the ability to experience and process
canonical Wnt signaling in the hem lineage is a carefully controlled
phenomenon that is critical for normal development of the brain.
S16-03
Intermediate progenitors in cerebral cortex development
R. Hevner
University of California San Diego, Pathology, La Jolla, USA
Intermediate progenitors (IPs) are a type of transit-amplifying cell
in developing cortex, marked by expression of transcription factor
Tbr2. IPs produce the majority of cortical pyramidal-projection
neurons, and are themselves derived from neural stem cell (NSC)-
like radial glial progenitors (RGPs) that express transcription factor
Sox9. Lineage tracing shows that RGPs produce large columnar
clones of neurons, while IPs produce small clones of neurons
(average size ~2 cells), often limited to one layer. IP progeny
frequently undergo asymmetric daughter cell apoptosis. In IPs, Tbr2
regulates hundreds of downstream target genes to drive the
transition from progenitor to cortical neuron identity, and regulate
diverse biological processes, such as the IP cytoskeleton, cell-cell
signaling, and regional and laminar identity of daughter neurons.
Comprehensive analysis of gene regulation by Tbr2 reveals context-
speciﬁc functions of Tbr2 in cortical development.
S16-04
Mechanisms generating cell-type diversity in cerebral
cortex
S. Hippenmeyer
IST Austria, Developmental Neuroscience, Klosterneuburg, Austria
The concerted production of the correct number and diversity of
neurons and glia is essential for intricate neural circuit assembly. In the
developing cerebral cortex, radial glia progenitors (RGPs) are
responsible for producing all neocortical neurons and certain glia
lineages. We recently performed a quantitative clonal analysis by
exploiting the unprecedented resolution of the genetic MADM
(Mosaic Analysis with Double Markers) technology and discovered
a high degree of non-stochasticity and thus deterministicmode ofRGP
behavior. However, the cellular and molecular mechanisms control-
ling the precise pre-programmed RGP lineage progression through
proliferation, neurogenesis and gliogenesis remain unknown. To this
end we use quantitative MADM-based experimental paradigms at
single RGP resolution to deﬁne the cell-autonomous functions of
candidate genes and signaling pathways controlling RGP-mediated
cortical neuron and glia genesis and postnatal stem cell behavior.
Ultimately, our results shall translate into a deeper understanding of
brain function and why human brain development is so sensitive to
disruption of particular signaling pathways in pathological neurode-
velopmental and psychiatric disorders.
© 2019 The Authors
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S17 The needs of a synapse: How dendritic and axonal organelles serve
synaptic function
S17-01
Positioning of secretory organelles in dendrites: focus on
f-actin
M. Mikhaylova
University Medical Center Hamburg-Eppendorf, UKE Center for
Molecular Neurobiology, ZMNH, RG Neuronal Protein Transport,
Hamburg, Germany
Organelle positioning within neurites is required for proper
neuronal function. In dendrites with their complex cytoskeletal
organization, transport of organelles is guided by local special-
izations of the microtubule and actin cytoskeleton, and by
coordinated activity of different motor proteins. Here, we focus
on the actin cytoskeleton in the dendritic shaft and describe dense
structures consisting of longitudinal and branched actin ﬁlaments.
These actin patches are devoid of microtubules and are frequently
located at the base of spines, or form an actin mesh around
excitatory shaft synapses. Using lysosomes as an example, we
demonstrate that the presence of actin patches has a strong impact
on dendritic organelle transport, as lysosomes frequently stall at
these locations. We provide mechanistic insights on this pausing
behavior, demonstrating that actin patches form a physical barrier
for kinesin-driven cargo. In addition, we identify myosin Va as
an active tether which mediates long-term stalling. This correla-
tion between the presence of actin meshes and halting of
organelles could be a generalized principle by which synapses
control organelle trafﬁcking.
S17-02
Retrograde trafﬁcking and local signaling of trkB-
containing amphisomes at presynaptic terminals
Michael. R. Kreutz
Leibniz Institute for Neurobiology, RG Neuroplasticity, Magdeburg,
Germany
Amphisomes derive from fusion of autophagosomes with late
endosomes and biogenesis of both organelles occurs predominantly
at axon terminals. Non-degradative roles of autophagy have been
barely described. Here we show that in neurons BDNF/TrkB trafﬁck
in amphisomes and signal at presynaptic boutons during retrograde
transport to the soma. Local signaling and inward transport is
orchestrated by the Rap GTPase-activating (RapGAP) protein
SIPA1L2, which connects TrkB amphisomes to a dynein motor.
The association with autophagosomes regulates the RapGAP
activity of SIPA1L2, and thereby the retrograde trafﬁcking and
local signaling of TrkB. Following induction of presynaptic
plasticity amphisomes dissociate from dynein at boutons, and this
enables local signaling and promotes transmitter release. Accord-
ingly, sipa1 l2 knockout mice show impaired BDNF-dependent
presynaptic plasticity. Collectively, the data suggest that TrkB-
signaling endosomes are in fact amphisomes that during retrograde
transport have local signaling capacity in the context of presynaptic
plasticity.
S17-03
Unconventional protein trafﬁcking in neurons
M. Kennedy
University of Colorado School of Medicine, Pharmacology, Aurora,
USA
Regulated synthesis and movement of proteins between cellular
organelles is central to diverse forms of biological adaptation and
plasticity. In neurons, the repertoire of channel, receptor and
adhesion proteins displayed on the cell surface directly impacts
cellular development, morphology, excitability and synapse func-
tion. The immensity of the neuronal surface membrane and its
division into distinct functional domains presents a challenging
landscape over which proteins must navigate to reach their
appropriate functional domains. I will present recent data from my
lab dissecting the trafﬁcking itinerary of nascent integral membrane
proteins as they travel from their sites of synthesis inside the cell to
their sites of function at the cell surface. I will introduce a new
approach we have developed for selectively initiating protein
trafﬁcking from different subcellular locations, which will help
unravel when, where and how proteins trafﬁc to and from different
neuronal compartments.
S17-04
Unveiling unconventional golgi-related organelles in
peripheral axons and their role in regeneration
C. Gonza´lez, L. Vargas-Saturno, J. Gallardo, N. Venegas, A. Couve
Universidad de Chile, Neuroscience Department and Biomedical
Neuroscience Institute BNI, Santiago, Chile
New models for the regulation of the axonal proteome have
emerged not only based on local synthesis but also on trafﬁcking of
proteins. Axons contain mRNAs for membrane proteins, ribosomes
and endoplasmic reticulum elements that support the presence of a
local biosynthetic machinery. The increasing number of studies
reporting axonal trafﬁc of transmembrane proteins and the presence
of some Golgi apparatus (GA) markers suggests the presence of this
organelle in axons. Nevertheless, the canonical stacked membranous
structure of GA has not been detected in axons. We hypothesized
that a simpliﬁed but efﬁcient GA-like structure is present in axons
that allows its maintenance and assist in the restoration functionality
after injury.
The presence and distribution of Golgi components was evalu-
ated in axons from mice sciatic nerve. We locally disrupted the ER
to Golgi trafﬁcking exposing a distal portion of sciatic nerve to the
ArfGEFs inhibitors Golgicide-A (GCA) and Brefeldin-A (BFA). We
evaluated the axonal regeneration in embryonic DRG cultures using
a microﬂuidic chamber that allows the separation of axons and cell
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bodies in different compartments. Disruption of ER to Golgi
trafﬁcking in isolated axons was achieved with GCA and BFA.
The Golgi markers TGN38, Golgi satellite (pGolt), Galactosyl-
transferase (Gal-T) and Mannosidase-II (Mns-II) were detected in
nodal and internodal regions of myelinated axons. pGolt displayed a
high co-distribution (~70%) with Gal-T and Lamp. GCA and BFA
reduce the particles of pGolt, Gal-T and Mns-II in isolated axons
from sciatic nerve.
Our data suggest that Golgi components are present in peripheral
axons. These components may constitute a mixed organelle con-
formed by Lamp, pGolt and Gal-T markers that might be part of an
unconventional Golgi apparatus adapted to axonal requirements.
© 2019 The Authors
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S17 The needs of a synapse: How dendritic and axonal organelles serve synaptic function
S18 Repeating themes of tandem repeat toxicity in neurological disorders
S18-01
Molecular mediators and environmental modulators of
pathogenesis in huntington’s disease
A. Hannan1, T. Renoir1, G. Kong1, S. Li1, C. Love1, J. Liew1,
C. Mo1,2, C. Gubert1
1University of Melbourne, Florey Institute of Neuroscience and
Mental Health, Parkville, Australia
2University of Chicago, Department of Neurobiology, Chicago,
USA
We have been investigating how various environmental manip-
ulations selectively alter gene expression, cellular plasticity and
associated cognitive processes and behaviours. Huntington’s disease
(HD) is one of over 50 tandem repeat disorders and involves a triad
of psychiatric, cognitive and motor symptoms. In a transgenic
mouse model of HD we have shown that expansion of the tandem
repeat encoding a polyglutamine tract of the mutant huntingtin
protein leads to a spatiotemporally speciﬁc cascade of molecular,
cellular and behavioural abnormalities. We have also demonstrated
that environmental enrichment can delay onset of the affective
(depression-like), cognitive and motor endophenotypes. Environ-
mental enrichment and physical exercise induce changes in gene
expression, which exhibit temporal speciﬁcity and regional selec-
tivity, and also act as cognitive enhancers. These ﬁndings have been
extended to include stress manipulations in HD mice, and environ-
mental manipulations in other preclinical models. Most recently, we
have discovered that gut microbiota are altered at an early stage of
pathogenesis. We are pursuing this ﬁrst evidence of gut dysbiosis in
HD, with respect to pathogeneic mechanisms and novel therapeutic
targets. These approaches may also facilitate the development of
‘enviromimetics’, novel therapeutics which mimic or enhance the
beneﬁcial effects of cognitive stimulation and physical activity. We
are further exploring the impact of speciﬁc environmental and
pharmacological interventions, including environmental enrichment,
exercise and stress, and the relevance of these discoveries in mice to
clinical HD. Our ﬁndings have implications for the development of
novel therapeutic approaches to delay onset and slow progression of
HD.
S18-02
The role of oligodendroglia in Huntington disease
M. Pouladi1,2,3
1National University of Singapore, Department of Medicine,
Singapore, Singapore
2National University of Singapore, Department of Physiology,
Singapore, Singapore
3Agency for Science, Technology and Research A*STAR,
Translational Laboratory in Genetic Medicine TLGM, Singapore,
Singapore
White matter abnormalities and oligodendroglial changes are
common features of neurodegenerative disorders, although their
aetiology is poorly deﬁned. A long-held assumption is that the white
matter atrophy observed in neurodegenerative disorders is simply a
secondary outcome of the progressive neuronal loss that manifests
with advancing disease. This assumption has been difﬁcult to
examine on the molecular and microstructural levels directly in pre-
symptomatic individuals prior to onset of neuronal loss, owing to
the invasiveness of the techniques involved. In this talk, I will
present our recent studies investigating the aetiology and conse-
quences of oligodendroglial dysfunction in animal models of
Huntington disease, a trinucleotide repeat disorder and the most
common genetic cause of dementia. I will further discuss the
implications of a better understanding of white matter pathology for
the development of therapies for neurodegenerative diseases.
S18-03
Targeting ran proteins improves phenotypes in C9orf72
BAC ALS/FTD mice
L. Ranum1, L. Nguyen1, F. Montrasio2, O. Bardhi1, S. Guo1, S. K.
Tusi1, K. Nakamura1, M. B. Coronel1, N. Sonenberg3, J. Grimm2, T.
Zu1
1University of Florida, Center for NeuroGenetics, Gainesville, USA
2Neurimmune AG,, Schlieren, Switzerland
3McGill University, Biochemistry, Montreal, Canada
Microsatellite expansion mutations cause more than 48 neuro-
logic diseases. In 2011, we discovered that in the absence of an
AUG or near cognate initiation codon, expanded CAG and CUG
repeats can express homopolymeric proteins from all three reading
frames. We and others have demonstrated that RAN translation
occurs in a growing number of repeat expansion disorders including:
spinocerebellar ataxia type 8 (SCA8), C9orf72 amyotrophic lateral
sclerosis / frontotemporal dementia (ALS/FTD), Huntington’s
disease (HD) and myotonic dystrophy (DM). An emerging theme
is that coding and non-coding expansion mutations are bidirection-
ally expressed, producing two mutant RNAs and up to six mutant
proteins. We now show that RAN translation can be regulated both
in vitro and in vivo through the PKR/eIF2a phosphorylation
pathway. In cells, steady state levels of several types of RAN
proteins are increased by PKR overexpression and decreased by
inhibiting PKR. In C9orf72 BAC transgenic ALS/FTD mice,
inhibiting PKR through AAV expression of the dominant negative
PKR-K296R protein decreases RAN protein pathology in vivo and
improves behavioral phenotypes. These data are consistent with a
model in which chronic activation of the PKR pathway by repeat
expansion RNAs favor RAN translation and that blocking this
pathway in mice reduces RAN protein accumulation and mitigates
disease. These data suggest that targeting the PKR pathway may be
a fruitful therapeutic approach to treat C9orf72 ALS/FTD and for
other repeat expansion diseases. In a separate study we show that
targeting RAN proteins with human antibodies improves behavior,
decreases neurodegeneration and increases survival in C9orf72
ALS/FTD BAC transgenic mice. These data demonstrate RAN
proteins play a central role in C9orf72 ALS/FTD and describe novel
approaches for the treatment of C9 and other RAN-protein diseases.
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S18-04
Non-AUG initiated translation of nucleotide repeats in
fragile x-associated disorders
P. Todd
University of Michigan, Neurology, Ann Arbor, USA
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an age-
related inherited neurodegenerative disorder affecting > 1 in 4000
people. FXTAS results from a CGG nucleotide repeat expansion in
the 5’ untranslated region (UTR) of FMR1. Expanded CGG-repeats
allow aberrant translation of cryptic homopolymeric proteins
through a repeat-associated non-AUG initiated translation mecha-
nism (CGG RAN translation). The most abundant CGG RAN
generated protein, FMRpolyG, accumulates in ubiquitin-positive
neuronal inclusions in Drosophila, CGG repeat-expressing mice and
FXTAS patients. RAN translation is necessary for CGG repeats to
elicit toxicity in Drosophila, neurons and mice. This lecture will
cover recently published and unpublished work exploring the
mechanisms by which RAN translation occurs at CGG repeats and
other nucleotide repeat expansions, with a special emphasis on the
roles of cellular stress pathways in this process. In addition, I will
present data related to a potential native function for CGG repeats
and RAN translation in the regulation of the fragile X gene, and
provide evidence that either directly or indirectly targeting RAN
translation initiation suppresses disease relevant phenotypes and
enhances survival in disease model systems.
© 2019 The Authors
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S19 Cellular and molecular mechanisms of glial development
S19-01
Role of transcriptional and epigenetic regulation in glial
cells
A. Giangrande
IGBMC, Functional Genomics and Cancer, Illkirch, France
Glial represent major actors in neural differentiation/physiology
and the absence or defects in this cell population leads to major
human pathologies as diverse as cancer, neurodegeneration and
autoimmune disorders. It is therefore of paramount importance to
understand the biology of glial cells. We have identiﬁed and
characterized the molecular pathway leading to the differentiation of
glia in Drosophila. These cells arise from multipotent precursors that
can be assimilated to the vertebrate neural stem cells. More recently,
we have started the analysis of the glial chromatin landscape and
have identiﬁed a cell-speciﬁc epigenetic signature that allows glial
cell function. This constitutes the ﬁrst evidence of a single signature
controlling speciﬁc biological processes in a differentiated cell type
and highlights the importance of chromatin modiﬁcations in the
function of the nervous system.
S19-02
Glia-ECM interactions control peripheral nerve integrity
and function
V. Auld, A. Hunter, M. Gilbert, M. Das
University of British Columbia, Zoology, Vancouver, Canada
Glial cells are critical the protection and function of the
nervous system and disruption of glial function leads nervous
system defects. The Drosophila nervous system is encased in a
highly conserved layer of glial cells, the perineurial glia, which
are in turn covered by a specialized extracellular matrix (ECM).
The function of perineurial glia and their interaction with the
ECM is just beginning to be elucidated and we are investigating
the mechanisms and functional importance of this interaction in
the peripheral nervous system. We found that integrins and
laminins are key to glial sheath development and maintenance.
Loss of integrins and focal adhesions disrupts the glial wrap of
peripheral nerves, disrupts animal locomotion and is lethal. We
have identiﬁed a new partner for integrin mediated glia-ECM
interactions, the transmembrane Ig domain protein, Basigin/
CD147/EMMPRIN. Loss of this highly conserved protein from
the perineurial glia leads to an unexpected phenotype of
compression of the glia and ECM in the peripheral nerves.
Perineurial glial compression results in breakage of the glial
cytoskeleton. Disruption of the peripheral nerves leads to reduced
locomotion and death. We found Basigin is expressed in close
proximity to integrin and functions with integrins in the
perineurial glia. Reduction of integrins or the integrin-binding
protein Talin can rescue the nerve compression phenotypes. Our
results indicate that Basigin regulates the integrin-based focal
adhesion complexes in order to uphold the structure of the glia-
extracellular matrix sheath.
S19-03
Motor exit point (MEP) glia: novel myelinating glia that
bridge CNS and PNS myelin
S. Kucenas
University of Virginia, Department of Biology, Charlottesville, USA
Traditionally, the CNS and PNS have been considered two halves
of a single organ, connected only by motor and sensory axons.
However, identiﬁcation of a CNS-derived peripheral glial popula-
tion called perineurial glia challenged this view and led us to
hypothesize that development of spinal motor nerves may involve
other CNS-derived glial populations. To investigate ithis hypothesis,
we used in vivo, time-lapse imaging, single cell ablation/fate-
mapping and genetic perturbation in zebraﬁsh, and discovered that
spinal motor nerve root axons are populated by a second, CNS-
derived glial population that is distinct from perineurial glia and
neural crest-derived Schwann cells, which we call motor exit point
(MEP) glia. Once in the periphery, these cells divide and produce
glia that myelinate spinal motor root axons. Recently, we have
focused on thoroughly characterizing this novel glial population by
investigating its development, maintenance and function. Develop-
mentally, we discovered that these cells share a common ventral
spinal cord precursor with oligodendrocyte progenitor cells (OPC),
the cells that ultimately differentiate into oligodendrocytes and
ensheath CNS axons in a fatty membrane known as myelin.
However, unlike OPCs, MEP glia migrate out of the CNS, associate
with and myelinate axons in the PNS and function to restrict OPCs
to the spinal cord. Therefore, for all intents and purposes, they are
peripheral glia. However, this simple designation does not capture
the complexity of this cell population. Therefore, using genetics and
in vivo imaging, we are investigating whether MEP glia are more
like oligodendrocytes or Schwann cells, or alternatively, if they are a
hybrid cell population with characteristics of both lineages and
determining the potential of these cells to replace both central and
peripheral myelinating glia upon demyelination.
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S19-04
Transcriptional control in myelinating glia: from extrinsic
signals to intrinsic factors and networks
M. Wegner
FAU Erlangen-N€urnberg, Institute of Biochemistry, Erlangen,
Germany
Development of myelinating glia is under control of a complex
gene regulatory network with transcription factors at its core and
chromatin modifying complexes and regulatory RNAs as additional
components. By changing functional interactions within the network,
extracellular signals drive lineage progression, eventually culminat-
ing in terminal differentiation and myelination. In my presentation,
several examples will be given for important functional interactions
within the regulatory network of oligodendroglial cells and how their
alterations inﬂuence developmentalmyelination in the central nervous
system of mammals. This will include the calcium-dependent
activation of Nfat proteins and the induction of Myrf expression at
the time of terminal differentiation as important modulatory events
with impact on the transcriptional activity of Sox10 and as triggers of
the myelination event.
© 2019 The Authors
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S20 SUMOylation in Health and Disease: From synaptic function to
neurodegeneration
S20-01
Extranuclear protein sumoylation in neurons
J. Henley, K. Talandyte, L. Lee, R. Seager, K. Wilkinson
University of Bristol, School of Biochemistry, Centre for Synaptic
Plasticity, Bristol, United Kingdom
SUMOylation acts as a biochemical switch that regulates a wide
and diverse array of cellular processes. The dynamic balance
between SUMO conjugation, mediated by a restricted set of
SUMOylation enzymes, and deSUMOylation mediated by SUMO
proteases controls substrate protein function, and is essential for cell
survival. While predominantly studied as a nuclear protein modi-
ﬁcation, it is now clear that SUMOylation of proteins outside the
nucleus play direct roles in controlling synaptic transmission,
neuronal excitability, mitochondrial dynamics and adaptive
responses to cell stress. Furthermore, alterations in protein
SUMOylation are observed in a wide range of neurological and
neurodegenerative diseases, and several extranuclear disease-
associated proteins have been shown to be directly SUMOylated.
Nonetheless, how SUMOylation of speciﬁc substrates is orches-
trated to control diverse cellular pathways is a major unresolved
question. Here I will discuss our recent mechanistic ﬁndings on how
SUMOylation and deSUMOylation of speciﬁc synaptic and mito-
chondrial proteins are central to neuronal function and viability.
S20-02
Sumoylation of alpha-synuclein in the pathogenesis of
parkinson’s disease
S. Engelender
Technion-Israel Institute of Technology, Dept. of Biochemistry,
Haifa, Israel
Parkinson’s disease (PD) is characterized by the neuronal
accumulation of a-synuclein and death of dopaminergic neurons
in the substantia nigra. At post-mortem examination, neurons from
PD patients show the presence of inclusions, known as Lewy
bodies, which are primarily composed of aggregated/ﬁbrillated a-
synuclein. Although the aggregation of a-synuclein is likely
involved in the pathogenesis of the disease, the mechanisms
responsible for its accumulation and aggregation in PD have
remained elusive. We have previously shown that monoubiquitina-
tion by SIAH ubiquitin-ligase promotes the proteasomal degradation
of a-synuclein. This monoubiquitination is dynamic, and when not
properly degraded by the proteasome, monoubiquitinated a-
synuclein promptly aggregates in cells. More recently, we found
that the degradation and aggregation of a-synuclein are further
controlled by another post-translational modiﬁcation, SUMOylation.
We identiﬁed PIAS2 as an endogenous SUMO-ligase for a-
synuclein. SUMOylation by PIAS2 decreases a-synuclein
monoubiquitination, leading to decreased a-synuclein proteasomal
degradation and triggering a-synuclein accumulation. SUMOylation
by PIAS2 also directly promotes the aggregation of a-synuclein
in vitro and in cells. In addition, a-synuclein disease mutants are
more readily SUMOylated, suggesting that increased SUMOylation
may play a role in the aggregation of a-synuclein in patients with
familial PD. Supporting a more widespread role of SUMOylation in
PD, the levels of SUMOylated a-synuclein and PIAS2 are increased
in sporadic PD brains. Therefore, we raise the possibility that
SUMOylation may play a role in the accumulation and aggregation
of a-synuclein in the disease. Targeted inhibition of a-synuclein
SUMOylation may help prevent the build-up of pathological a-
synuclein in PD.
S20-03
The role of FOXP1/2 sumoylation in neurodevelopment
G. Konopka
UT Southwestern Medical Center, Department of Neuroscience,
Dallas, USA
Post-translational modiﬁcations play an important role in direct-
ing the function or expression of proteins. Sumoylation has been
shown to regulate protein function in numerous ways including
subcellular localization, transcriptional regulation, and stability. In
the central nervous system, sumoylation of proteins has been
identiﬁed in regulating ion channel activity, synaptic formation and
function, mRNA transport in axons, and mitochondrial function.
However, few studies have demonstrated a role for sumoylation in
directing mammalian organismal behavior. In our work, we have
examined the role of sumoylation of two related transcription
factors, FOXP1 and FOXP2, in the development of the neocortex
and cerebellum, respectively. Both of these transcription factors
have strong genetic links to human brain disorders: variants in
FOXP2 are associated with speech and language disorders and
variants in FOXP1 are among the most common de novo autism
spectrum disorder variants. We have found that sumoylation of
FOXP2 is necessary for Purkinje cell development and cerebellar-
related behaviors including ultrasonic vocalizations. Sumoylation of
FOXP1 is necessary for proper cortical lamination development and
may underlie deﬁcits in socially-relevant behaviors. Ongoing work
in the lab is devoted to understanding the cell-type speciﬁc role of
each of these transcription factors within the developing brain, and
results from single-cell RNA-sequencing in a number of conditional
knockout lines will be presented.
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S20-04
Sumoylation impact on synaptic function and alzheimer
disease pathology
P. Fraser1, H. Takamura1,2, S. Matsuzaki3,2, T. Katayama2, O.
Arancio4
1University of Toronto, Tanz Centre, Toronto, Canada
2Osaka University, United Graduate School of Child Development,
Osaka, Japan
3Wakayama Medical University, Department of Pharmacology,
Wakayama, Japan
4Columbia University, Taub Institute for Research on Alzheimer’s
Disease and the Aging Brain, New York, USA
Small ubiquitin-like modiﬁers (SUMOs) can affect a number of
cellular pathways. Recent evidence has shown SUMOylation
contributions to neuronal function and may be important factors in
the amyloid and tau pathology in Alzheimer disease (AD) and
related disorders. We demonstrated in a transgenic mouse model
that over-expression of SUMO1 results in an impairment of synaptic
development leading to cognitive deﬁcient. In contrast, comparable
SUMO2 transgenic animals display normal development and no
changes in learning and memory. There has been a debate on the
effects of SUMO1 and SUMO2 on amyloid pathology and, to
resolve this issue, we have recently investigated the impact of
SUMOylation on processing of the amyloid precursor protein (APP)
leading to the production and deposition of the amyloid-b (Ab)
peptide. Using the SUMO1 transgenics, an in vivo model was
developed by the generation of double transgenic mice over-
expressing human SUMO1 and a mutant APP. The SUMO1-APP
mice displayed normal APP processing but exhibited increased
insoluble Ab and plaque density accompanied by increased synaptic
loss, more pronounced synaptic and cognitive deﬁcits. These
ﬁndings suggest a potential impairment in Ab clearance as opposed
to increased amyloid production. In contrast, SUMO2-APP double
transgenic mice were less affected by amyloid deposition suggesting
a more beneﬁcial response of SUMO2 to the AD-related stress
conditions. Our ﬁndings indicate a more detrimental impact of
SUMO1 on amyloid and tau pathology and possible protective
effects associated with higher levels of expression for SUMO2.
© 2019 The Authors
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S21 Regulation of Neuronal Development and Plasticity by Palmitoylating
Enzymes
S21-01
Post-translational palmitoylation and its regulation of
synaptic plasticity
S. Bamji
University of British Columbia, Cellular and Physiological
Sciences, Vanvouver, Canada
Palmitoylation is the most common post-translational lipid mod-
iﬁcation in the brain. It involves the addition of the fatty acid,
palmitate, onto substrate proteins and is exceedingly important for
protein trafﬁcking and cell signaling. Enzymes that mediate palmi-
toylation consist of a family of 23 proteins zDHHC enzymes.
Approximately 41% of all identiﬁed synaptic proteins are substrates
for palmitoylation, and the differential palmitoylation of synaptic
substrates has been reported in response to synaptic activity suggest-
ing a role for palmitoylation in the regulation of synapse plasticity.
Using proteomic analysis, we have identiﬁed a list of synaptic proteins
that are differentially palmitoylated in the hippocampus of mice that
have undergone fear conditioning, as well as in hippocampal cultures
following chemical LTP. We have also identiﬁed zDHHC enzymes
that are differentially expressed and modiﬁed in response to synaptic
activity, to provide amoremechanistic understanding of how zDHHC
enzymes regulate synapse plasticity.
S21-02
Control of neuronal excitability by palmitoylation-
dependent ion channel clustering at the axon initial
segment
G. Thomas1,2
1Temple University School of Medicine, Shriners Hospitals
Pediatric Research Center, Philadelphia, USA
2Temple University School of Medicine, Anatomy and Cell Biology,
Philadelphia, USA
Precise control of neuronal excitability is essential for normal
behaviour and cognition, while aberrant excitability is a hallmark of
many neurological diseases. One key factor that controls the threshold
of excitability is the clustering of voltage-gated ion channels at the
Axon Initial Segment (AIS), but how such clustering is regulated is
not fully understood. Ion channel clustering at other subcellular
locations is often controlled by modiﬁcation of Membrane-Asso-
ciated Guanylate Kinase (MAGUK) family ‘scaffold’ proteins with
the lipid palmitate, a process called palmitoylation. Using unbiased
screening we identiﬁed PSD-93, the only MAGUK family member
that localizes to the AIS, as a direct interactor and substrate of a
palmitoyl acyltransferase (PAT), ZDHHC14. Using lentiviral-
mediated shRNA knockdown we assessed how loss of Zdhhc14
affects clustering of PSD-93 and AIS-localized potassium channels to
which PSD-93 binds. Results of these studies provide new insights
into the regulation of ion channel clustering at the AIS, and have
broad implications for our understanding of physiological regulation
of excitability and its dysfunction in conditions such as epilepsy.
S21-03
Activity-dependent palmitoylation regulates SynDIG1
function in excitatory synapse development and plasticity
E. Diaz
UC Davis School of Medicine, Pharmacology, Davis, USA
A key neural mechanism of learning and memory is thought to be
activity-dependent changes in synaptic AMPA receptors (AMPAR)
levels. Hebbian plasticity such as long-term potentiation and long-
term depression is an associative, positive feedback mechanism to
allow individual synapses to strengthen or weaken depending on
increased or decreased activity, respectively. Homeostatic plasticity
is a negative feedback mechanism that maintains the strength of
synapses relative to each other and is referred to as ‘synaptic
scaling.’ Together, Hebbian and homeostatic plasticity are necessary
to allow for input-speciﬁc changes in synaptic strength while
maintaining a dynamic yet stable framework of neuronal excitabil-
ity. Palmitoylation is a reversible post-translational modiﬁcation that
regulates membrane association, trafﬁcking, and protein–protein
interactions. Activity-dependent palmitoylation regulates localiza-
tion and function of many synaptic proteins including AMPARs and
PSD-95 in an activity-dependent manner. Previously, we showed
that overexpression or knock-down (KD) of the AMPAR-interacting
transmembrane protein SynDIG1 (SD1, Synapse Differentiation
Induced Gene 1) in dissociated rat hippocampal neurons increases or
decreases, respectively, AMPA-R synapse size and number by
~50% with immunocytochemistry and electrophysiology (Kalash-
nikova et al., 2010). The magnitude of this effect matches that of the
transmembrane AMPAR associated regulatory proteins (TARPs)
and PSD-95, suggesting that SD1 is a critical regulator of AMPAR
synaptic strength. Intriguingly, SD1 localization at excitatory
synapses increases dramatically in response to network silencing
by tetrodotoxin, a manipulation established to induce upscaling of
synaptic AMPARs. Furthermore, KD of SD1 in hippocampal
neurons prevents AMPAR-mediated homeostatic upscaling of
synaptic strength, a form of non-Hebbian plasticity, in response to
activity silencing. We propose that SD1 localization at synapses and
regulation of synaptic strength is mediated by activity-dependent
palmitoylation.
S21-04
Determining the role of palmitoylation in subcellular
localization of ankyrins
P. Jenkins1,2, J. Philippe1
1University of Michigan Medical School, Pharmacology, Ann
Arbor, USA
2University of Michigan Medical School, Psychiatry, Ann Arbor,
USA
Ankyrins are a family of scaffolding proteins that recruit ion
channels, transporters, and cell adhesion molecules to specialized
membrane domains, critical for cell polarity and cell function. Two
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members of the ankyrin family, ankyrin-G (encoded by ANK3) and
ankyrin-B (encoded by ANK2), exhibit distinct subcellular localiza-
tion and unique functions in neurons, despite high homology. In
neurons, ankyrin-G recruits voltage-gated sodium channels, the cell
adhesion molecule neurofascin, as well as the cytoskeletal protein
bIV spectrin at the axon initial segment, a critical membrane domain
responsible for initiation of the action potential. In contrast, ankyrin-
B is localized throughout the neuronal plasma membrane, with the
exception of the AIS, where it plays roles in maintenance of the
distal axon cytoskeleton, control of axonal projections, and partic-
ipation of axonal transport. To date, the mechanisms underlying the
distinct localization of ankyrin-G and ankyrin-B in neurons remain
unclear. Previous studies showed that S-palmitoylation of ankyrin-G
is required for its speciﬁc localization at the epithelial cell lateral
membrane, as well as its ability to build this membrane. We show
here the ﬁrst evidence that all neuronal isoforms of ankyrin-G and
ankyrin-B are S-palmitoylated in mouse cortex, providing prece-
dence for studying palmitoylation as a regulator of ankyrin
localization and function in neurons. Furthermore, we show that
ankyrin-B and ankyrin-G palmitoylation is mediated by a partially
distinct set of zDHHC PATs in HEK293T cells, suggesting that
differential ankyrin recognition by zDHHC PATs may govern their
distinct localization in neurons.
© 2019 The Authors
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S22 Is Multiple Sclerosis a Primary Cytodegenerative Disease?
S22-01
Primary neurodegeneration in multiple sclerosis
R. Dutta, B. Trapp
Cleveland Clinic Foundation, Dept Neurosciences NC30,
Cleveland, USA
Demyelination is the pathological hallmark of multiple sclerosis
(MS). Neurodegeneration, however, is the major cause of
irreversible neurological disability in MS and occurs as a
consequence of demyelination. Axons are transected in acute
white-matter (WM) lesions, and cortical and deep gray-matter
(GM) demyelination cause neuronal and axonal loss. GM atrophy
is one of the best MRI predictors of neurological disability in MS
patients and can occur independently of brain WM lesions. Based
upon these MRI observations, it has been proposed that demyeli-
nation and neurodegeneration can be independent events in MS.
We recently described a novel subtype of MS (myelocortical MS;
MCMS) characterized by demyelination of the spinal cord and
cerebral cortex, but not of cerebral WM. MCMS patients were
severely disabled at time of death and comprised ~12% of our
autopsy cohort. Clinical histories of MCMS patients were
indistinguishable from typical MS (TMS) patients with cerebral
WM demyelination, which provided a platform to compare
cortical neuronal density in MCMS, TMS, and aged-matched
control brains. Compared to control cortices, neuronal densities
were lower in MCMS cortices than in TMS. These studies provide
pathological evidence that cerebral WM demyelination and
cortical neuronal degeneration can be independent events in
MCMS. MRI of MCMS brains detected cerebral WM regions that
contained T2 hyperintensities, T1 hypointensities, and altered
magnetization transfer ratios (MTR). Pathological analyses of
these regions detected swollen myelinated axons. We propose that
increased water content in swollen myelinated axons is partially
responsible for regions with T1 hypointensities and reduced MTR.
These studies all support the concept that brain WM demyelina-
tion and neurodegeneration can be independent events in MS. If a
primary neurodegenerative process exists in individuals with MS,
then associated molecular changes could initiate a secondary
immune-mediated demyelination. This work was funded by the
NIH.
S22-02
Inﬂammatory demyelination and the loss of
oligodendroglial support of axonal energy metabolism
K.-A. Nave
Max Planck Institute of Experimental Medicine, Dept. of
Neurogenetics, Goettingen, Germany
Loss of CNS myelin in multiple sclerosis (MS) and its animal
models (EAE) is invariably associated with axonal dysfunction and
degeneration, but the underlying mechanisms are not well
understood. Myelin sheaths isolate axonal compartments from
the extracellular milieu and thus from rapid access to glucose. We
hypothesize that the structural integrity of myelin, including the
system of nm-wide cytosolic channel that connect the oligoden-
droglial soma with the periaxonal innermost layer of myelin, are
required for efﬁcient metabolic support of axons by lactate. Here,
non-synaptic activation of oligodendroglial NMDA receptors by
high frequency spiking, a proxy of energy demands, enhances
glucose import and lactate supply. Moreover, myelin itself is an
energy reserve and oligodendroglial lipid metabolism contributes
to the axonal energy balance. Is myelin under acute immune attack
most detrimental to axon function and survival compared to
completely demyelinated axons, because the latter are less likely to
‘starve’? This hypothesis can be tested in Mbp neomice, a novel
mouse mutant with mosaic dysmyelination of the spinal cord.
These mice appear signiﬁcantly more ‘resistant’ to the effects of
MOG-EAE despite the large fraction of unmyelinated spinal cord
axons.
S22-03
Neurodegeneration, grey matter pathology, and an
aberrant AXO-myelinic synapse: lessons from
histopathology and post mortem MRI
B. ‘t Hart, J. Geurts
Vumc, Anatomy & Neurosciences, Amsterdam, Netherlands
Multiple sclerosis (MS) is classically considered to be an
autoimmune, inﬂammatory demyelinating disease of the CNS.
However, it has been questioned whether inﬂammation and/or
autoimmunity are really at the root of the disease, and it has been
proposed that MS might, in fact, be a primary degenerative
disorder (Stys, 2012). This lecture will review several studies that
contributed to this discussion from the viewpoint of human
histopathology and (post mortem) MRI. Firstly, over the past
twenty years it has become abundantly clear that gray matter
damage in this ‘prototypical WM disease’ is widespread (Geurts
2008, 2012). Interestingly, it seems that demyelinated gray matter
lesions are hardly, if at all, driven by inﬂammation. Instead, vast
quantities of myelin products seem to gather extracellularly around
blood vessels and in the meninges (Kooi 2009), presumably to be
transported away to the cervical lymph nodes (Fabriek 2005).
Chronic white matter damage, too, was shown to be largely non-
inﬂammatory (Seewann et al, 2009) except for a microglial
component reminiscent of that in primary neurodegenerative
diseases such as Alzheimer’s. Granted, these might be ‘late stage
effects’, when neuroinﬂammation and neurodegeneration have
largely become separate pathophysiological processes. However,
even in the earliest phases of the disease, gray matter degeneration,
especially thalamic atrophy, is already pertinent (Schoonheim
2012). And ongoing research suggests that, at the microscopic
level, communication between MS axons and their surrounding
myelin is fundamentally disrupted in several different ways, even
before an inﬂammatory response is apparent. Whether these
pathological processes build up to a sufﬁciently convincing model
for ‘inside-out’ cytodegeneration in MS is now up for debate.
However, they already seem to provide a tantalizing challenge to
the existing dogma of primary autoimmunity.
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S22-04
Multiple sclerosis as a protein misfolding disorder
P. Stys
University of Calgary, Clinical Neurosciences, Calgary, Canada
Data in recent years support the notion that MS is a convolution
of degeneration and auto-immunity, together conspiring to produce
the broad spectrum of relapsing-remitting and progressive clinical
phenotypes. However, after decades of intensive investigation, the
primary trigger of the disease is unknown. Data will be presented
supporting the hypothesis that MS is a protein misfolding disorder,
similar to other traditional neurodegenerative diseases. Intracerebral
inoculation of transgenic mice with human MS brain homogenate
induces a myelinopathy together with an astro- and microgliosis
similar to the non-lesional white matter pathology found in human
MS. Subtle behavioral disturbances (spatial learning deﬁcits on
water maze testing) accompany the histological abnormalities.
Passaging (inoculation of na€ıve mice with brain homogenate of MS-
inoculated mice) also continued to transmit pathology. Control
human brain homogenate (e.g. chronic encephalitis, Alzheimer’s,
Lewy body disease) did not reproduce the transmitted pathology.
We hypothesized that prion protein may play a role: immunodeple-
tion of PrP and intracerebral inoculation signiﬁcantly reduced the
transmitted pathology. Together these data suggest that a transmis-
sible misfolded protein might play a role, and the prion protein
could be directly or indirectly involved in the generation of the
subtle MS-like pathology in recipient mice. This mechanism might
lead to myelin disruption, subsequent axonal compromise, and
release of antigenic debris that secondarily promote auto-immune
inﬂammation in the human.
© 2019 The Authors
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S23 RNA modiﬁcation in the brain and behaviour
S23-01
RNA modiﬁcations and memory
T. Bredy
Queensland Brain Institute, QBI, Brisbane, Australia
In this talk, I will discuss our recent work characterized experience-
dependent subcellular compartmentalization of m6A modiﬁed RNA
and it’s role in adaptive behavior. Speciﬁcally, we are testing the
hypothesis that m6A is necessary for RNA localization and that there
is a distinct pool of m6Amodiﬁed RNA at the synapse that inﬂuences
fear exitinctionmemory. I will also touch on other RNAmodiﬁcations
that appear to occur in a learning- or activity-dependent manner.
S23-02
RNA modiﬁcations and translational regulation at
neuronal synapses
O. Wang1, Y. Fujiwara1, R. Roy1, M. Sukegawa1, S. Ramasamy1,
W.-T. Hong1, I. Oomoto1, K. Lida3
1Kyoto University, Institute for Integrated Cell-Material Sciences
iCeMS, Kyoto, Japan
2Kyoto University, Graduate School of Biostudies, Kyoto, Japan
3Kyoto University, Medical Research Support Center, Kyoto, Japan
Single-cell analyses have revealed that compared to other cell
types in the brain, neurons not only contain higher RNA content, but
also higher RNA species diversity, suggesting complex translational
regulatory mechanisms that neurons actively engage to achieve their
function. Our lab has focused on a cellular mechanism that
physically uncouple transcription and translation through mRNA
trafﬁcking and local translation at neuronal synapses. We have
found that the synaptically pre-deposited mRNA species can
respond to stimuli that induce long-term synaptic plasticity and
undergo synapse-, transcript-, and stimulus-speciﬁc translation. In
search for the regulatory components accounting for such molecular
speciﬁcity, we have found that methylation at adenosine RNA
residues (m6A) can functionally mark the localized RNA species
and positively regulate their translation. Reducing proteins that
recognize and bind to m6A in neurons causes neuronal deﬁcits in
spinogenesis, activity-dependent spine maturation, synaptic trans-
mission, learning, and memory retention. Furthermore, we show that
RNA methylation-mediated translational mechanisms may play
important roles in regulating dynamic microtubule networks that
underlie building and remodeling of neuronal circuits.
S23-03
Neuronal allocation to an engram underlying memory
B. Walters, S. Josselyn
Hospital for Sick Children Research Institute, Neurosciences &
Mental Health Program, Toronto, Canada
Understanding how the brain uses information is a fundamental
goal of neuroscience. Several human disorders (ranging from
autism spectrum disorder to Alzheimer’s disease) may stem from
disrupted information processing. Therefore, this basic knowledge
is not only critical for understanding normal brain function, but
also vital for the development of new treatment strategies for
these disorders. Memory may be deﬁned as the retention over time of
internal representations gained through experience, and the capacity
to reconstruct these representations at later times. Long-lasting
physical brain changes (‘engrams’) are thought to encode these
internal representations. The concept of a physical memory trace
likely originated in ancient Greece, although it wasn’t until 1904 that
Richard Semon ﬁrst coined the term ‘engram’. Despite its long
history, ﬁnding a speciﬁc engram has been challenging, likely
because an engram is encoded at multiple levels (epigenetic,
synaptic, cell assembly). Here, I will discuss our previous studies
examining how speciﬁc neurons are recruited or allocated to an
engram, and our recent work examining how neuronal membership
in an engram may change over time or with new experience.
S23-04
Epitranscriptomic regulation of protein synthesis,
learning and memory by N6-methyladenosine (m6A)
X. Zhuang1, J. Koranda1, M. J. Patel1, J. Y. Delgado1, L. O. Vaasjo1,
J. Thome1, W. Fu1, L. Mo1, H. Shi2, C. He2
1University of Chicago, Department of Neurobiology, Chicago,
USA
2University of Chicago, Department of Chemistry, Chicago, USA
N6-methyl(m6A) is the most abundant mammalian inmRNA
modiﬁcation. It proreguRNA splicing, trans locali transand degra-
dation, and may play a central role in the spatial and temporal
control of protein synthesis. The emergence of m6A research is
largely facilitated by the disof its key effector pro m6A “writers”
(methyl e.g. METTL14) install m6A, “erasers” (demethyl remove
m6A, and “readers” (e.g. YTHDF1, 2 and 3) recogand bind to m6A
to determine the fate of the modiﬁed RNA. Different m6A readers
may mediate different downfunctional consequences of m6A
modiﬁcation of mRNA. Recent data sugthat m6A deﬁciency impairs
both neuroment and adult central nervous system func and impairs
learning and memory. We have found that conditional deletion of
Mettl14 in striatonigral neu striatopallidal neuor dopamine neurons
impaired reinforcement learning and motor learning, and altered reto
cocaine. Constitutive deletion of Ythdf1 impaired prosynthesis,
altered synaptic trans and impaired many different forms of learning
and memory. Because m6A modiﬁes thousands of transand proim-
pacts many neufunc it’s been a challenge to systematically inhow
the dynamic reguof the m6A pathway may control speprotein
synthesis with good spatial and temporal resolution to affect
synaptic plasticity, learning and memory. We are using geapproto
manipulate the effector pro What the targets of these effector prons
are, how the above manipulations may affect transglobally or transof
spemRNAs, synaptic proturnover, synaptic trans plasticity, denspine
morphology and beare being systematically examined.
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S24 Biological and Therapeutic Roles of Lipids in Neurodegeneration
S24-01
Role of isoprenoids in autophagy and prion-like spread of
abeta
E. P. de Chaves, A. Viveiros, K. Smith, A. Mohamed
University of Alberta Faculty of Medicine and Dentistry,
Pharmacology, Edmonton, Canada
The development of disease-modifying therapies for Alzheimer’s
disease (AD) is hampered by the incomplete understanding of early
pathogenic mechanisms that lead to disease. Brain accumulation of
beta amyloid (Ab) drives AD pathogenesis. Recent ﬁndings indicate
that cell to cell transmission of Ab by a ‘prion-like’ spread
mechanism contributes to AD progression.
We discovered that Ab42 inhibits synthesis of cholesterol and
isoprenoids (FPP and GGPP) by impairing maturation of SREBP2.
This inhibition results in reduction of protein prenylation in neurons
exposed to Ab42. We also demonstrated that protein prenylation is
reduced in brain cortex of TgCRND8 mice.
A cellular process that relies heavily on prenylated proteins such as
Rabs, is autophagy. Extensive autophagic-lysosomal pathology in AD
brain plays a role in disease pathogenesis, although the underlying
mechanisms are not well understood. Previous reports demonstrated
that reversing autophagy dysfunction by genetic manipulation
improves pathophysiology and rescues memory performance in
TgCRND8 mice. Using the tandem reporter mcherry-GFP-LC3 we
found that Ab42-induced inhibition of protein prenylation causes a
blockade of autophagic ﬂux in cultured cells and in vivo. Recovery of
protein prenylation with GGPP normalizes autophagic ﬂux in both
paradigms. Moreover, Rab7 localization to autophagosomes, which is
required for autophagy progression, is reduced in Ab42-treated neurons
and GGPP corrects Rab7 prenylation and its subcellular localization.
When autophagy is compromised, cells may resource to protein
secretion to alleviate stress. Ab is released in extracellular vesicles
(EVs). Using imaging ﬂow cytometry and nanoparticle tracking
analysis we showed that Ab-induced autophagy blockade increases
EVs secretion favoring cell-to-cell spreading of Ab.
Our studies identify the reduction of protein prenylation as a key
mechanism of autophagy dysfunction and prion-like spread in AD
models and provide novel autophagy-related targets with disease-
modifying value.
S24-02
Gangliosides in Huntington’s disease and beyond
S. Sipione
University of Alberta, Pharmacology, Edmonton, Canada
Huntington’s disease (HD) is a neurodegenerative disorder
caused by the expansion of a CAG trinucleotide repeat in the ﬁrst
exon of the HTT gene. The resulting mutant huntingtin (mHTT)
protein acquires toxic conformations and aggregates within the cells,
leading to neuronal dysfunction and death. We have shown that
levels of ganglioside GM1, a glycosphingolipid highly enriched in
the brain, are decreased in HD models. Administration of exogenous
GM1 reduces levels of soluble and aggregated mutant huntingtin in
HD mouse brains, slows down neurodegeneration and corrects
motor as well as cognitive and psychiatric-like dysfunctions in HD
mice. The underlying mechanisms and potential implications for
other protein misfolding diseases will be discussed.
S24-03
TREM2 regulates microglial cholesterol metabolism upon
chronic phagocytic challenge
G. D. Paolo
Denali Therapeutics Inc., Discovery Biology, South San Francisco,
USA
Loss of function variants of TREM2, an immune receptor
expressed in microglia, increase Alzheimer’s disease (AD) risk.
REM2 was shown to recognize lipids and mediate myelin phago-
cytosis, but its role in microglial lipid metabolism is unknown.
Combining chronic demyelination paradigms and cell sorting
techniques with RNA sequencing and lipidomics, we found that
wildtype microglia acquire a disease-associated microglia (DAM)
transcriptional state, while TREM2-deﬁcient microglia remain
largely homeostatic, which leads to neuronal damage. TREM2-
deﬁcient microglia maintain phagocytic activity of myelin debris,
but are incompetent at clearing myelin lipids, including cholesterol,
resulting in marked intracellular accumulation of cholesteryl esters.
Defects in cholesterol metabolism were replicated in aged wildtype
microglia and in cultured TREM2-deﬁcient macrophages upon
myelin challenge, where they required ACAT1 activity. TREM2
therefore mediates a transcriptional program required to process
cholesterol overload during chronic phagocytic activity, which
ultimately prevents neuronal damage. These results provide a
potential mechanism for pathogenic lipid accumulation in AD.
S24-04
Effects of Niemann-Pick type C1-deﬁciency on synaptic
function and brain energy metabolism
B. Karten
Dalhousie University, Biochemistry and Molecular Biology,
Halifax, Canada
Cholesterol is an essential component of all animal membranes,
and inﬂuences membrane ﬂuidity, permeability, membrane protein
function, and ﬁssion and fusion processes. The brain is the most
cholesterol-rich organ in the human body. While most brain
cholesterol is in myelin and metabolically nearly inert, non-myelin
cholesterol is actively turned over at rates comparable to peripheral
tissues. Changes in brain cholesterol homeostasis are linked to
synaptic dysfunction and neurodegeneration. Niemann-Pick Type C
(NPC) disease, caused in most cases by loss of the late endosomal
NPC1 protein, is characterized by cholesterol accumulation in the
endocytic pathway, redistribution of cholesterol and a range of
cellular dysfunctions. Here, I will discuss the effects of NPC1
deﬁciency on synaptic function and energy metabolism.
© 2019 The Authors
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S25 Molecular dynamics of the inhibitory post synapse and the tuning of
synaptic inhibition
S25-01
Membrane dynamics at the inhibitory synapse and the
regulation of inhibitory transmission
J. Kittler
UCL, Neuroscience, Physiology and Pharmacology, London,
United Kingdom
Synaptic inhibition plays a critical role in regulating the balance
of excitation and inhibition in the brain and thus information
processing. The strength of inhibition is determined to a large extent
by the number of GABAAreceptors (GABAARs) at synaptic sites,
which can be controlled by receptor stabilisation in the synaptic
membrane. I will talk about our ongoing work to better understand
the machinery important for targeting and stabilization of
GABAARs at synapses and the role played by key inhibitory
synaptic components including Neuroligin 2 and the GABAAR
receptor accessory protein LHFPL4/Garlh. I will also focus on the
mechanisms regulating the trafﬁcking dynamics of Neuroligin 2 at
the synapse and how this can regulate inhibitory synapse strength.
Our elucidation of the mechanisms important for controlling the
membrane dynamics of inhibitory synaptic components opens up
new avenues for understanding the regulation of inhibitory trans-
mission in the brain.
S25-02
Nanoscale organization of the inhibitory synapse
K. Smith, K. Crosby, S. Gookin, J. Garcia, K. Hahm, M. Dell’Acqua
University of Colorado Denver, Pharmacology, Aurora, USA
Inhibitory synapses mediate the majority of synaptic inhibition in
the brain, thereby controlling neuronal excitability, ﬁring and
plasticity. Although essential for neuronal function, the central
question of how these synapses are organized at the subsynaptic
level remains unanswered. Here, we utilize 3D super-resolution
microscopy to image key components of the inhibitory postsynaptic
domain and presynaptic terminal, revealing that inhibitory synapses
are organized into nanoscale subsynaptic domains (SSDs) of the
gephyrin scaffold, GABAARs and the active zone protein, Rab3-
interacting molecule (RIM). Gephyrin SSDs cluster GABAAR
SSDs, demonstrating nanoscale architectural interdependence
between scaffold and receptor. GABAAR SSDs strongly associate
with active zone RIM SSDs, indicating an important role for
GABAAR nanoscale organization near sites of GABA release.
Finally, we ﬁnd that in response to elevated activity, synapse growth
is mediated by an increase in the number of postsynaptic SSDs,
suggesting a modular mechanism for increasing inhibitory synaptic
strength.
S25-03
Proteo-connectomics to discover novel synaptic
proteomes and mechanisms of inhibition in vivo
S. Soderling
Duke University Medical Center, Cell Biology, Durham, USA
This talk will present work on identifying novel proteins at
synapses using in vivo proximity biotinylation and high resolution
quantitative mass spectrometry. I will ﬁrst present data on the
diverse proteomes of synapses within multiple neuron types in vivo.
This will be followed by data on the synaptic and behavioral
analysis of knockout mice for a newly discovered GABAergic
postsynaptic protein.
S25-04
Tuning of synaptic inhibition by the second messenger cl-
S. Levi
INSERM UMR1270, Institut du Fer a Moulin, Paris, France
Upon activation by GABA, GABAARs open a selective chloride/
bicarbonate conductance. The direction of chloride (Cl-) ﬂux through
the channel depends on transmembrane Cl- gradients. Therefore, Cl-
homeostasis critically determines the polarity and efﬁcacy of
GABAergic transmission in the brain. Pharmaco-resistant epilepsies
are often associated with altered Cl- homeostasis. It is therefore
crucial to discover novel mechanisms regulating neuronal Cl-
homeostasis that may help develop new and efﬁcient treatment for
these forms of epilepsy and other diseases associated with impaired
inhibition, such as neuropathies and some neuropsychiatric disorders.
The increase in [Cl–]i and subsequent depolarized shift in the
reversal potential of GABAAR-mediated currents (EGABA) observed
in the epileptic brain are most often attributed to reduced surface
expression/function of the neuronal K+-Cl- cotransporter KCC2,
responsible for Cl- export. Furthermore, up-regulation of the Na+-
K+-Cl- cotransporter NKCC1, which imports chloride into neurons,
also increases [Cl–]i and alters EGABA. Although the mechanisms
regulating KCC2 in the pathology have been extensively explored
revealing altered membrane trafﬁcking, those controlling NKCC1
remain largely unknown.
We recently demonstrated the contribution of a novel signaling
pathway in the regulation of KCC2. We showed that KCC2 is
regulated by GABAergic signaling through Cl--dependent phos-
phorylation of KCC2 Threonine residues T906/1007. Cl- acts as a
secondary messenger in this regulation by tuning the activity of the
Cl- sensitive With No lysine (K) serine-threonine kinase WNK1 and
its downstream effectors Ste20 Proline Asparagine Rich Kinase
(SPAK) and Oxydative Stress Response kinase 1 (OSR1). Interest-
ingly, WNK kinases not only promote KCC2 T906/T1007 but also
NKCC1 T203/T207/T212 phosphorylation. This results in dual
modulation of Cl- transport by inhibiting KCC2 and by activating
NKCC1; both regulations leading to elevation in intracellular Cl-
level. Therefore, inhibiting the neuronal WNK/SPAK/OSR1-
dependent KCC2 and NKCC1 Threonine phosphorylation may
normalize the membrane expression/function of the transporters and
reduce [Cl–]i. The WNK/SPAK/OSR1 signaling pathway may thus
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represent a promising therapeutic target for preventing the emer-
gence of acquired epilepsies.
We aim to characterize the WNK/SPAK/OSR1 pathway in
central neurons and to determine whether genetic or pharmacological
inhibition of this cascade has beneﬁcial effects for epilepsy. Our
project will help uncover novel and promising therapeutic strategies
for several forms of acquired epilepsy, and other pathologies in
which inhibition is altered, such as neuropathic pain and psychiatric
disorders.
© 2019 The Authors
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S26-01
Coordinated disassembly and reassembly of the nuclear
pore complex in C9orf72 and sporadic ALS
J. Rothstein, A. Coyne, L. Hayes
Johns Hopkins University, Brain Science Institute; Dept of
Neurology, Baltimore, USA
An intronic GGGGCC hexanucleotide repeat expansion in the
C9orf72 gene is the most common cause of Amyotrophic Lateral
Sclerosis (ALS) and Frontotemporal Dementia (FTD). Nucleocyto-
plasmic transport is tightly controlled by the nuclear pore complex
and has recently emerged as a prominent pathomechanism under-
lying multiple neurodegenerative diseases including C9orf72 ALS/
FTD. Using super resolution structured illumination microscopy, we
evaluated the distribution of individual nucleoporins in nuclei
isolated from control and C9orf72 iPSC derived motor neurons and
postmortem human motor cortex to identify a subset of nucleoporins
lost from the nuclear pore complex in an age dependent manner. A
combination of overexpression and knock down experiments reveals
that POM121, an integral scaffolding nucleoporin, coordinates the
disassembly and reassembly of the nuclear pore complex in post-
mitotic neurons impacting nucleocytoplasmic transport and cellular
toxicity. Together, these data suggest that POM121 is an integral
nucleoporin in the maintenance of the nuclear pore complex in post-
mitotic neurons and loss of POM121 from the nuclear pore complex
in C9orf72 ALS/FTD initiates a pathological cascade affecting
nuclear pore complex integrity and function.
S26-02
Axonal transport defects in motor neurons derived from
ALS patients
L. Van Den Bosch
VIB-KU Leuven Center for Brain & Disease Research,
Neurosciences, Leuven, Belgium
The dissociation of the motor axon from the muscle, resulting in
denervated neuromuscular junctions, leads to muscle atrophy and
paralysis during amyotrophic lateral sclerosis (ALS). The retraction
of the axon and ultimately the selective death of the motor neuron is
the hallmark of the disease. The mechanism leading to this ‘dying
back’ phenomenon is not known in approximately 90% of patients,
while in the remaining patients a number of different genes are
mutated. SOD1, TARDBP, FUS and C9orf72 are the most
important ones. We generated and characterized induced pluripotent
stem cells (iPSCs) from ALS patients with mutations in TARDBP,
FUS and hexanucleotide repeats in C9orf72, as well as from healthy
controls. Patient-derived motor neurons showed a number of typical
characteristics for each of the mutations, including a higher fraction
of insoluble TDP-43 in the lines from patients with mutated
TARDBP, cytoplasmic mislocalisation of FUS in the lines from
mutant FUS patients and the production of dipeptide repeat proteins
(DPRs) in the C9orf72 patient lines. In addition, we observed
hypoexcitability, as well as progressive axonal transport defects in
all the ALS lines. These axonal transport defects could be rescued
by genetic correction using CRISPR/Cas9 of the FUS mutation in
the patient-derived iPSCs. Moreover, these defects could be
reproduced by expressing mutant FUS in human embryonic stem
cells (hESCs) conﬁrming that these pathological changes were
mutant FUS dependent. Pharmacological inhibition, as well as
genetic silencing of histone deacetylase 6 (HDAC6), increased a-
tubulin acetylation and restored the axonal transport defects in
patient-derived motor neurons. In conclusion, we observed axonal
transport defects in human-derived motor neurons from patients
with different genetic causes that we could correct by using selective
HDAC6 inhibitors.
S26-03
Pathogenic signiﬁcance of aberrant glia phenotypes in
amyotrophic lateral sclerosis
L. Barbeito
Institut Pasteur Montevideo, Neurodegeneration Lab, Montevideo,
Uruguay
Amyotrophic Lateral Sclerosis (ALS) is characterized by degen-
eration of upper and lower motor neurons accompanied by the
proliferation of reactive microglia in affected regions. Previous
reports have shown the occurrence of aberrant glial phenotypes
associated to spinal motor neurons. However, the origin and
pathogenic signiﬁcance of glial diversity in ALS remain unknown.
By using cell cultures and immunohistochemistry we have charac-
terized abnormal microglia cell phenotypes interacting with motor
neurons in the spinal cord of SOD1G93A rat spinal cords and
autopsied tissues from sporadic ALS subjects. We will present
evidence of two distinct and yet-unknown phenotypes of microglia
identiﬁed by the expression of senescent and microglia progenitor
markers. Both subsets of microglia cells accumulate adjacent to
degenerating spinal motor neurons, representing intriguing cell
targets for approaching ALS pathogenesis and therapeutic.
S26-04
Translational control of immune response in ALS
J. Kriz
Laval University, Psychiatry and Neurosciences, Quebec City,
Canada
Microglia are the principal immune cells of the brain. Once
activated, in injured and/or diseased brain, microglia can acquire a
wide repertoire of the context-dependent immune proﬁles. However,
at present, the molecular mechanisms involved in the control of
microglia polarization proﬁles remain elusive. By using an in vivo
model-system for analysis of the dynamic translational state of
microglial ribosomes with mRNAs as input and newly synthesized
peptides as an output, recently created in our laboratory (Boutej
et al., Cell Rep 2017),we found a marked dissociation of microglia
mRNA and protein molecular signatures following an acute innate
immune challenge. The results revealed that highly up-regulated and
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ribosome-associated mRNAs were not translated resulting in
creation of two distinct microglia molecular signatures: i) a highly
specialized pro-inﬂammatory mRNA and ii) immunomodulatory/
homeostatic protein signature. The most striking divergence was
observed in the key immune NF-jB network where we found that
the cluster of highly up-regulated LPS-induced and polysome-
associated mRNAs such as Saa3, Lcn2 ccl3, ccl5 (from 15-30 fold
increase at mRNA level) were indeed not translated. As mechanism,
we discovered a selective 3’UTR-mediated translational suppression
of highly expressed mRNAs. Moreover, we identiﬁed a novel and
previously unknown role for RNA binding protein SRSF3 as a
master suppressor/regulator of innate immune genes translation. The
complex analysis of mRNA/protein networks in ALS affected and
chronically activated microglia suggests existence of SRSF3
mediated, ribosome-based mechanism/check point involved in the
control of highly regulated mRNAs in vivo.
© 2019 The Authors
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S27-01
Differential impact of mTOR signaling in oligodendrocytes
during myelination in spinal cord and brain
W. Macklin1, H. Hathaway1, A. Almeida1, K. Dahl1, T. Wood2
1University of Colorado School of Medicine, Department of Cell
and Developmental Biology, Aurora, USA
2New Jersey Medical School, Rutgers University, Department of
Pharmacology, Newark, USA
The differentiation of oligodendrocyte precursor cells (OPCs)
into mature, myelinating oligodendrocytes in the central nervous
system involves numerous intracellular signaling cascades, includ-
ing the mammalian target of rapamycin (mTOR) pathway. mTOR
exists in two complexes: Raptor-containing mTOR complex 1
(mTORC1) and Rictor-containing mTOR complex 2 (mTORC2),
and our studies deleting mTOR or the separate complexes in
oligodendrocytes suggest that the signaling requirements for OPC
differentiation and myelination may be region-speciﬁc. Our earlier
studies demonstrated that deletion of mTOR or mTORC1 (Raptor)
in 2’,3’-cyclic-nucleotide 3’-phosphodiesterase (CNP)-Cre mice
reduced myelination in spinal cord, with little impact in brain. By
contrast, deletion of mTORC2 (Rictor) in CNP-Cre mice had little
impact in either CNS region.The current study focuses on the role
of mTORC2 in OPC differentiation by deleting Rictor in platelet-
derived growth factor receptor alpha (PDGFRa)-Cre mice, where
recombination is speciﬁc to OPCs. By contrast to the earlier
studies, conditional deletion of Rictor in OPCs had a dramatic
impact on OPC differentiation and myelination, but in these
animals the impact was in brain, not spinal cord or optic nerve.
Consistent with this phenotype, downstream mTORC2 signaling
was impacted more in brain than spinal cord in PDGFRa-Cre x
Rictor ﬂ/ﬂ mice. Interestingly, side-by-side analysis of control
brain and spinal cord lysates revealed unexpected differences in
signaling pathway usage in these CNS regions. These studies
supported by NIH NS080223
S27-02
mTOR and telomerase-new partners in the brain?
G. Saretzki
Newcastle University, Institute for Cell and Molecular Biosciences,
Newcastle upon Tyne, United Kingdom
Telomerase is a special reverse transcriptase that in its
canonical function maintains telomeres in dividing cells using a
template on its inherent RNA component. Additionally, the protein
part TERT (Telomerase Reverse Transcriptase) has various non-
canonical functions. For example, it can localize to mitochondria
under increased stress and protect cells in vitro from oxidative
stress, DNA damage and apoptosis. Recently it has been
demonstrated that TERT protein persists in adult neurons in the
brain and data emerge suggesting that it might have a protective
function in these post-mitotic cells as well. We have recently
demonstrated that TERT protein accumulated speciﬁcally in brain
mitochondria from of mice that have undergone short-term dietary
restriction (DR) and rapamycin treatment. This increased mito-
chondrial localization correlated to lower levels of oxidative stress
in brain mitochondria. Decreased mTOR signalling is a known
mediator for the beneﬁcial effects of DR. Feeding mice with
rapamycin for 4 months increased brain mitochondrial TERT and
reduced ROS release from brain mitochondria while telomerase
activity was not changed. Importantly, the beneﬁcial effects of
rapamycin on mitochondrial function were absent in brains and
ﬁbroblasts from ﬁrst generation TERT -/- mice, and when TERT
shuttling was inhibited by the Src kinase inhibitor bosutinib. In
summary, our data suggests that the mTOR signalling pathway
impinges on the mitochondrial localisation of TERT protein,
which might in turn contribute to the protection of the brain by
DR or rapamycin against age-associated mitochondrial ROS
increase and cognitive decline. Thus, we have discovered that
the mTOR pathway might be involved in the TERT localization to
mitochondria and its beneﬁcial effects in brain mitochondria
in vivo.
S27-03
Aberrant mTOR signaling contributes to development of
alzheimer-like dementia
M. Perluigi
Sapienza university of rome, Biochemical science, Rome, Italy
The mTOR pathway represents a key growth and survival
pathway involved in several diseases. Numerous studies linked
the alterations of mTOR signaling to age-dependent cognitive
decline, pathogenesis of Alzheimer disease (AD) and AD-like
dementia in Down syndrome (DS). DS is the most frequent
chromosomal abnormality that causes intellectual disability. The
neuropathology of AD in DS is complex and involves impaired
mitochondrial function, defects in neurogenesis, increased oxida-
tive stress, altered proteostasis and autophagy. Recent studies
from our laboratory employing specimens from DS individuals
and DS mouse models showed that aberrant mTOR signalling is
an early degenerating event in the brain that contributes to
acceleration of Ab and tau deposition and to the development of
AD-like cognitive decline. Our results showed the hyperactivation
of PI3K/AKT/mTOR axis in the brains of subjects with DS, with
or without AD pathology, in comparison to healthy controls, as
well as in a Tg mouse model of the disease. These data were
associated with decreased autophagy, inhibition of IRS1 and
GSK3b activity. Moreover, our results suggest that aberrant
activation of PI3K/Akt/mTOR axis acts in parallel to RCAN1 in
phosphorylating tau, in DS and DS/AD. These ﬁndings represent
a strong rationale to test therapeutic strategies aimed to restore
mTOR signaling and among drug candidates, we tested the effects
of intranasal rapamycin treatment to slow the progression of AD
in DS. We demonstrated that rapamycin, administered for
3 months by intranasal route, led to improved cognition in DS
mice with no effects at peripheral organs. The favorable outcomes
of rapamycin treatment seem to rely on its ability to rescue
molecular pathways associated with aberrant mTOR
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phosphorylation, including metabolism of APP and Tau, activa-
tion of AMPK and reduction of oxidative stress.
S27-04
Antidepressant effect of ketamine via the mTOR pathway
and eEIF4E-dependent mRNA translation
N. Sonenberg1, A. Aguilar-Valles1,2,3, A. Skaleka1, E. Matta-
Camacho1,3, M. J. Eslamizade1,2, D. D. Gregorio4, A. Torres-
Berrio5, G. Gobbi4, J.-C. Lacaille2
1McGill University, Department of Biochemistry, Montreal, Canada
2Universite de Montreal, Department of Neurosciences, Montreal,
Canada
3Carleton University, Department of Neuroscience, Ottawa, Canada
4McGill University, Department of Psychiatry, Montreal, Canada
5Friedman Brain Institute, Icahn School of Medicine at Mount
Sinai, Nash Family Department of Neuroscience, New York, USA
mTOR controls many cellular functions, including mRNA
translation through phosphorylation and inactivation of the eukary-
otic initiation factor 4E (eIF4E) binding proteins (4E-BPs), which
supress translation by binding to the eIF4E. The latter is the mRNA
cap-binding protein that facilitates ribosome binding. The fast-acting
antidepressant drug ketamine activates the mammalian target of
rapamycin (mTOR) signaling pathway, which is essential for the
antidepressant effect of ketamine. We sought to determine whether
4E-BPs play a role in the antidepressant effect of ketamine, and
whether this pathway is activated in excitatory or inhibitory neurons.
Ketamine did not affect the immobility in the force-swim test (FST)
of Eif4ebp1-/- or Eif4ebp2-/- mice, but, as expected, it reduced
immobility in wildtype mice. Moreover, the effect of ketamine on
NSF (reduced latency to feed in a new environment) was not
observed in Eif4ebp2-/- and Eif4ebp1-/- mice. Mice lacking either
Eif4ebp1 or Eif4ebp2 in Camk2a+ cells, were resistant to the
antidepressant effects of ketamine, but responded normally to an
acute injection ﬂuoxetine. Conditional KO mice in Gad2 + cells
were also resistant to ketamine. Furthermore, Eif4ebp2-/- mice in
Gad2 + cells displayed reduced immobility in the FST without any
antidepressant treatment, suggesting a more preponderant role for
4E-BP2 in Gad2 + neurons in response to ketamine. These results
demonstrate that activation of eIF4E-dependent translation initiation
is required in both excitatory and inhibitory neurons for the
antidepressant effect of ketamine.
© 2019 The Authors
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